Search Result

Results for "

VEGF

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) Akt (21) Aldehyde Dehydrogenase (ALDH) (1) Angiotensin-converting Enzyme (ACE) (2) Annexin A (1) Antibiotic (7) Apoptosis (39) Aryl Hydrocarbon Receptor (1) Atg8/LC3 (1) Aurora Kinase (2) Autophagy (14) Bacterial (6) Bcl-2 Family (4) Bcr-Abl (1) Beclin1 (3) Btk (1) c-Kit (1) Cadherin (1) Calcium Channel (1) Caspase (6) CDK (4) Cholecystokinin Receptor (3) Complement System (4) COX (7) CXCR (2) Dihydroorotate Dehydrogenase (1) DNA/RNA Synthesis (3) Drug Intermediate (2) Drug Isomer (1) Drug Metabolite (1) EBI2/GPR183 (1) EGFR (3) Endogenous Metabolite (11) Ephrin Receptor (3) ERK (9) Estrogen Receptor/ERR (1) FAK (4) Farnesyl Transferase (1) FGFR (3) FLT3 (1) FXR (2) GSK-3 (2) HCV (2) HIF/HIF Prolyl-Hydroxylase (23) Histamine Receptor (8) HSP (2) HSV (1) HuR (1) Insulin Receptor (1) Integrin (7) Interleukin Related (7) Isotope-Labeled Compounds (6) JAK (1) JNK (4) Leukotriene Receptor (2) Liposome (4) Macrophage migration inhibitory factor (MIF) (1) MAP3K (1) MDM-2/p53 (4) MEK (3) Microtubule/Tubulin (2) Mitochondrial Metabolism (1) MMP (6) Monoamine Oxidase (1) mTOR (4) NADPH Oxidase (2) NF-κB (12) NO Synthase (1) Notch (2) p38 MAPK (5) Parasite (3) PARP (1) PD-1/PD-L1 (2) PDGFR (4) PERK (2) PGE synthase (1) Phosphodiesterase (PDE) (1) PI3K (11) Pim (1) PKC (2) PKD (1) PPAR (2) Prolyl Endopeptidase (PREP) (1) Proteasome (1) PTEN (3) Raf (4) RAR/RXR (1) Ras (2) Reactive Oxygen Species (ROS) (6) Reference Standards (18) RET (1) SARS-CoV (4) Small Interfering RNA (siRNA) (5) Sodium Channel (1) Src (3) SRPK (2) STAT (6) Survivin (1) TAM Receptor (1) TGF-β Receptor (1) Thrombin (1) Tie (5) Trk Receptor (1) TRP Channel (1) Tyrosinase (1) VEGFR (111)
By Research Areas:	Cancer (158) Cardiovascular Disease (52) Endocrinology (7) Infection (14) Inflammation/Immunology (49) Metabolic Disease (10) Neurological Disease (7)
Oligonucleotides:	Aptamers (1) Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNA drugs (2) Polymers (1) siRNAs (5)

220

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-132305

VEGFR-3-IN-1 1 Publications Verification	VEGFR	Cancer
VEGFR-3-IN-1 is a potent and selective VEGFR3 inhibitor with an IC₅₀ of 110.4 nM. VEGFR-3-IN-1 significantly inhibits proliferation and migration of VEGF-C-induced human dermal lymphatic endothelial cells (HDLEC), MDA-MB-231, and MDA-MB-436 cells by inactivating the VEGFR3 signaling pathway, and also effectively inhibits breast cancer growth .

HY-P990148

*Anti-Mouse VEGF-A Antibody (2G11-2A05)*	VEGFR	Cancer
Anti-Mouse VEGF-A Antibody (2G11-2A05) is a rat-derived anti-VEGF-A IgG2a, κ type antibody inhibitor, binding to mouse *VEGF-A* with high affinity. Anti-Mouse VEGF-A Antibody (2G11-2A05) shows good anti-tumor effect in gastric cancer xenograft models .

HY-P9951A

*Ranibizumab (anti-VEGF)* 1 Publications Verification RG-6321 (anti-VEGF)	VEGFR	Cardiovascular Disease
Ranibizumab (RG-6321) (anti-VEGF) is a humanized anti-VEGF monoclonal antibody fragment and can recognize all VEGF-A isoforms (VEGF110, VEGF121, and VEGF165) . Ranibizumab (anti-VEGF) slows vision loss in vivo and is used for wet age-related macular degeneration (AMD) research .

HY-108801

Aflibercept VEGF Trap; VEGF-TRAPR1R2; VEGF-trapR1	VEGFR	Cardiovascular Disease Metabolic Disease Cancer
Aflibercept (VEGF Trap) is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease .

HY-168279

VEGF-IN-1	VEGFR	Cancer
VEGF-IN-1 (compound 6) can reduce the release of *VEGF* in U87-MG cells and inhibit angiogenesis in vitro. VEGF-IN-1 can inhibit cell proliferation by inducing autophagy in tumor cells, with an IC₅₀ value of 28.35 μM for U87-MG cells .

HY-RS16537

Vegfa Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Vegfa Mouse Pre-designed siRNA Set A contains three designed siRNAs for Vegfa gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Vegfa Mouse Pre-designed siRNA Set A Vegfa Mouse Pre-designed siRNA Set A

HY-139822

VEGFR-2-IN-10	VEGFR	Cancer
VEGFR-2-IN-10 exhibits increased antiangiogenic potency (IC₅₀ = 0.7 μM) against VEGF-induced VEGFR2 phosphorylation without cytotoxic effects.

HY-RS15635

VEGFA Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
VEGFA Human Pre-designed siRNA Set A contains three designed siRNAs for VEGFA gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

VEGFA Human Pre-designed siRNA Set A VEGFA Human Pre-designed siRNA Set A

HY-RS22968

Vegfa Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Vegfa Rat Pre-designed siRNA Set A contains three designed siRNAs for Vegfa gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Vegfa Rat Pre-designed siRNA Set A Vegfa Rat Pre-designed siRNA Set A

HY-112337

VEGFR-2-IN-44	VEGFR PDGFR	Cancer
VEGFR-2-IN-44 (compound 4b) is a selective VEGF-R2 (Flk-1) inhibitor with an IC₅₀ value of 70 nM. VEGFR-2-IN-44 also inhibits PDGF-Rβ with an IC₅₀ of 920 nM .

HY-P9906A

Bevacizumab (PBS) Maximum Cited Publications 36 Publications Verification Anti-Human VEGF, Humanized Antibody (PBS)	VEGFR	Cancer
Bevacizumab, a humanized IgG1 monoclonal antibody, specifically binds to all *VEGF-A* isoforms with high affinity .

HY-108801A

*Aflibercept (VEGF* Trap)** 1 Publications Verification	VEGFR	Cardiovascular Disease Metabolic Disease Cancer
Aflibercept (VEGF Trap) is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease .

HY-P5558

KLTWQELYQLKYKGI	VEGFR	Inflammation/Immunology
KLTWQELYQLKYKGI (QK) is a VEGF mimicking peptide, binds to the VEGF receptors and competes with VEGF. KLTWQELYQLKYKGI is active in gastric ulcer healing in rodents when administered either orally or systemically. KLTWQELYQLKYKGI shows the ability to induce capillary formation and organization in vitro .

HY-18185

JNJ 17029259	VEGFR	Cancer
JNJ 17029259 is an orally active and selective *VEGF-R2* kinase inhibitor. JNJ 17029259 inhibits VEGF-mediated signal transduction. JNJ 17029259 has anti-angiogenic activity .

HY-P9906

Bevacizumab Maximum Cited Publications 36 Publications Verification Anti-Human VEGF, Humanized Antibody	VEGFR	Cancer
Bevacizumab, a humanized IgG1 monoclonal antibody, specifically binds to all *VEGF-A* isoforms with high affinity.

HY-109561

Pegaptanib sodium EYE001; NX1838	VEGFR	Metabolic Disease Inflammation/Immunology
Pegaptanib sodium is an RNA aptamer directed against vascular endothelial growth factor (VEGF)-165. Pegaptanib could be used for the study of neovascular age-related macular degeneration (AMD) .

HY-108868

Mersalyl Salirgan; Salurin; Salyrgan	HIF/HIF Prolyl-Hydroxylase VEGFR	Metabolic Disease
Mersalyl (Salirgan) is a potent vascular endothelial growth factor (VEGF) and hypoxia-inducible factor 1 (HIF-1) inducer. Mersalyl induces VEGF and ENO1 mRNA expression. Mersalyl shows diuresis effects .

HY-N7177

Hydroxytanshinone IIA	Drug Metabolite VEGFR	Cancer
Hydroxytanshinone IIA is a hydroxylated metabolite of Tanshinone IIA. Tanshinone IIA may suppress angiogenesis by targeting the protein kinase domains of *VEGF/VEGFR2* .

HY-P991384

DX-2240	Tie	Cancer
DX-2240 is a human monoclonal antibody (mAb) targeting TIE1. DX-2240 inhibits tumor growth and sensitizes tumor vasculature to anti-angiogenic agents (VEGF pathway inhibitors) .

HY-P5107

Low molecular weight protamine LMWP	VEGFR	Cancer
Low molecular weight protamine is a cell-penetrating peptide with vascular endothelial growth factor (VEGF) inhibitory activity. Low molecular weight protamine can inhibit tumor growth and is used in cancer research .

HY-176464

GSK2220691	TRP Channel	Inflammation/Immunology
SK2220691 is a potent TRPV4 inhibitor. SK2220691 inhibits pulmonary edema induced by GSK1016790. SK2220691 inhibits HCl-induced increases in key factors such as VEGF, keratinocyte-derived chemokine (KC; CXCL1), and granulocyte colony-stimulating factor (GCSF) .

HY-13892

Dovitinib dilactic acid CHIR-258 dilactic acid; TKI258 dilactic acid	VEGFR	Cancer
Dovitinib (dilactic acid) is an orally active inhibitor of VEGF kinase. Dovitinib (dilactic acid) inhibits receptor tyrosine kinases (RTKs) involved in solid and hematologic cancers and tumor angiogenesis .

HY-151465

HIF-1α-IN-4	HIF/HIF Prolyl-Hydroxylase	Cancer
HIF-1α-IN-4 is a HIF-1α inhibitor with an IC₅₀ value of 24 nM (in HEK293T cell). HIF-1α-IN-4 downregulates VEGF and PDK1 mRNA expressions under hypoxia. HIF-1α-IN-4 can be used in the research of cancer .

HY-18963

Lavendustin A RG-14355	EGFR	Cancer
Lavendustin A (RG-14355) is a potent, selective and ATP-competitive inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, with an IC₅₀ of 11 nM. Lavendustin A does not inhibit protein kinase A or C. Lavendustin A can suppress VEGF-induced angiogenesis .

HY-115436

LYG-202	Apoptosis	Cancer
LYG-202, a flavonoid, has potent anti-angiogenic and antitumor activity. LYG-202 inhibits VEGF-stimulated HUVEC migration and tube formation. LYG-202 induces cancer cell apoptosis .

HY-P5133

Synstatin (92-119) SSTN92-119	Integrin	Cancer
Synstatin (92-119) is an anti-tumor agent that inhibits angiogenesis and cancer cell invasion. Synstatin (92-119) down-regulates integrin α?β3 and reduces the activation of angiogenic growth factors VEGF and FGF-2 .

HY-135671

AhR modulator-1	Aryl Hydrocarbon Receptor VEGFR Estrogen Receptor/ERR	Endocrinology Cancer
AhR modulator-1 (compound 6-MCDF) is a selective and orally active aryl hydrocarbon receptor (AhR) modulator. AhR modulator-1 inhibits metastasis, in part, by inhibiting prostatic VEGF production prior to tumor formation. AhR modulator-1 also possess anti-estrogenic properties in rat uterus .

HY-P10521

Apolipoprotein KV domain (67-77)	VEGFR	Cancer
Apolipoprotein KV domain (67-77) is an 11-amino acid peptide identified from the KV domain of human apolipoprotein a (ApoA) with antiangiogenic and antitumor activities. Apolipoprotein KV domain (67-77) targets the angiogenic c-Src/ERK pathway by blocking activation signals received from vascular endothelial growth factor (VEGF). Apolipoprotein KV domain (67-77) can be used in cancer research .

HY-120417

JP-153	Src FAK	Cardiovascular Disease
JP-153 is the Src-FAK-Paxillin signaling inhibitor. JP-153 inhibits Src-dependent phosphorylation of paxillin (Y118) and downstream activation of Akt (S473). JP-153 reduces VEGF-induced migration and proliferation in retinal endothelial cells. JP-153 can be uesd for the study of neovascular eye disease .

HY-17369B

Tirofiban 4 Publications Verification L700462; MK383	Integrin	Cardiovascular Disease
Tirofiban (L700462) is a selective and reversible platelet integrin receptor (Gp IIb/IIIa) antagonist that inhibits fibrinogen binding to this receptor and has antithrombotic activity. Tirofiban induces proliferation and migration on endothelial cell by inducing production of VEGF. Tirofiban can significantly reduces myocardial no-reflow and ischemia-reperfusion injury by alleviating myocardial microvascular structural and endothelial dysfunction in the ischemic area .

HY-17369A

Tirofiban hydrochloride L700462 hydrochloride; MK383 hydrochloride	Integrin	Cardiovascular Disease
Tirofiban (L700462) hydrochloride is a selective and reversible platelet integrin receptor (Gp IIb/IIIa) antagonist that inhibits fibrinogen binding to this receptor and has antithrombotic activity. Tirofiban hydrochloride induces proliferation and migration on endothelial cell by inducing production of VEGF. Tirofiban hydrochloride can significantly reduces myocardial no-reflow and ischemia-reperfusion injury by alleviating myocardial microvascular structural and endothelial dysfunction in the ischemic area .

HY-17369

Tirofiban hydrochloride monohydrate 4 Publications Verification L700462 hydrochloride monohydrate; MK383 hydrochloride monohydrate	Integrin	Cardiovascular Disease
Tirofiban (L700462) hydrochloride monohydrate is a selective and reversible platelet integrin receptor (Gp IIb/IIIa) antagonist that inhibits fibrinogen binding to this receptor and has antithrombotic activity. Tirofiban hydrochloride monohydrate induces proliferation and migration on endothelial cell by inducing production of VEGF. Tirofiban hydrochloride monohydrate can significantly reduces myocardial no-reflow and ischemia-reperfusion injury by alleviating myocardial microvascular structural and endothelial dysfunction in the ischemic area .

HY-162011

GPR183 antagonist-2	EBI2/GPR183	Inflammation/Immunology
GPR183 antagonist-2 (compound 32) is a selective GPR183 antagonist with good water solubility and excellent pharmacokinetic properties. GPR183 antagonist-2 significantly reduces paw and joint swelling and gene expression of pro-inflammatory cytokines (MCP-1, MMPs, and VEGF) in a collagen-induced arthritis (CIA) mouse model in a dose-dependent manner. GPR183 antagonist-2 can be used in the study of autoimmune diseases .

HY-151466

HIF-1α-IN-5	HIF/HIF Prolyl-Hydroxylase Monoamine Oxidase	Cancer
HIF-1α-IN-5 is a HIF-1α inhibitor with an IC₅₀ value of 24 nM (in HEK293T cell). HIF-1α-IN-5 also inhibits MAO-A activity. HIF-1α-IN-5 downregulates VEGF and PDK1 mRNA expressions under hypoxia. HIF-1α-IN-5 can be used in the research of cancer .

HY-18963R

Lavendustin A (Standard) RG-14355 (Standard)	Reference Standards EGFR	Cancer
Lavendustin A (Standard) is the analytical standard of Lavendustin A. This product is intended for research and analytical applications. Lavendustin A (RG-14355) is a potent, selective and ATP-competitive inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, with an IC50 of 11 nM. Lavendustin A does not inhibit protein kinase A or C. Lavendustin A can suppress VEGF-induced angiogenesis[1][2].

HY-17369R

Tirofiban hydrochloride monohydrate (Standard) L700462 hydrochloride monohydrate (Standard); MK383 hydrochloride monohydrate (Standard)	Reference Standards Integrin	Cardiovascular Disease
Tirofiban (hydrochloride monohydrate) (Standard) is the analytical standard of Tirofiban (hydrochloride monohydrate). This product is intended for research and analytical applications. Tirofiban (L700462) hydrochloride monohydrate is a selective and reversible platelet integrin receptor (Gp IIb/IIIa) antagonist that inhibits fibrinogen binding to this receptor and has antithrombotic activity. Tirofiban hydrochloride monohydrate induces proliferation and migration on endothelial cell by inducing production of VEGF. Tirofiban hydrochloride monohydrate can significantly reduces myocardial no-reflow and ischemia-reperfusion injury by alleviating myocardial microvascular structural and endothelial dysfunction in the ischemic area .

HY-17369BR

Tirofiban (Standard) L700462 (Standard); MK383 (Standard)	Reference Standards Integrin	Cardiovascular Disease
Tirofiban (Standard) is the analytical standard of Tirofiban. This product is intended for research and analytical applications. Tirofiban (L700462) is a selective and reversible platelet integrin receptor (Gp IIb/IIIa) antagonist that inhibits fibrinogen binding to this receptor and has antithrombotic activity. Tirofiban induces proliferation and migration on endothelial cell by inducing production of VEGF. Tirofiban can significantly reduces myocardial no-reflow and ischemia-reperfusion injury by alleviating myocardial microvascular structural and endothelial dysfunction in the ischemic area .

HY-B0223

Albendazole 5 Publications Verification SKF-62979	Parasite Microtubule/Tubulin Autophagy Apoptosis Reactive Oxygen Species (ROS) VEGFR HIF/HIF Prolyl-Hydroxylase Antibiotic Bacterial	Infection Cancer
Albendazole (SKF-62979) is an orally active and broad-spectrum parasiticide with high effectiveness and low host toxicity, is used for the research of gastrointestinal parasites in humans and animals. Albendazole induces apoptosis and autophagy in cancer cells. Albendazole also inhibits tubulin polymerization and HIF-1α, *VEGF* expression, has antioxidant activity, and inhibits the glycolytic process in cancer cells .

HY-147712

PKC-IN-4	PKC	Inflammation/Immunology
PKC-IN-4 (compound 7l) is a potent and orally active aPKC inhibitor with an IC₅₀ of 0.52 µM. PKC-IN-4 inhibits TNF-α induced NF-κB activity in vitro. PKC-IN-4 blocks VEGF- and TNFα-induced permeability across the retinal vasculature .

HY-P99905

Efdamrofusp alfa 1 Publications Verification	VEGFR	Cardiovascular Disease Neurological Disease
Efdamrofusp alfa is a bispecific fusion protein. Efdamrofusp alfa is capable of neutralizing both VEGF isoforms and C3b/C4b. Efdamrofusp alfa can be used for the research of neovascular age-related macular degeneration (nAMD) and other complement-related ocular conditions .

HY-B0223R

Albendazole (Standard) SKF-62979 (Standard)	Reference Standards Parasite Microtubule/Tubulin Autophagy Apoptosis Reactive Oxygen Species (ROS) VEGFR HIF/HIF Prolyl-Hydroxylase Antibiotic Bacterial	Infection Cancer
Albendazole (Standard) is the analytical standard of Albendazole. This product is intended for research and analytical applications. Albendazole (SKF-62979) is an orally active and broad-spectrum parasiticide with high effectiveness and low host toxicity, is used for the research of gastrointestinal parasites in humans and animals. Albendazole induces apoptosis and autophagy in cancer cells. Albendazole also inhibits tubulin polymerization and HIF-1α, VEGF expression, has antioxidant activity, and inhibits the glycolytic process in cancer cells .

HY-N2666

5α-Hydroxycostic acid	VEGFR	Cancer
5α-Hydroxycostic acid, a eudesmane-type sesquiterpene, is isolated from the herb Laggera alata. 5α-Hydroxycostic acid inhibits angiogenesis and suppresses breast cancer cell migration through regulating *VEGF/VEGFR2* and Ang2/Tie2 pathways .

HY-P10550

VGB4	VEGFR	Cancer
VGB4 is a *VEGF-A* and *VEGF-B* antagonist peptide that duplicates two binding domains of *VEGF-B* (loop 1 and loop3) and are linked together by the receptor-binding domain of *VEGF-A* (loop3). VGB4 has significant anti-angiogenic and anti-tumor activities and can regulate tumor growth and metastasis through multiple mechanisms. VGB4 could be used in anti-tumor research .

HY-P99215

Parsatuzumab Anti-EGFL7; RG 7414	VEGFR	Cancer
Parsatuzumab (Anti-EGFL7; RG 7414) is a humanized monoclonal antibody, acts as an immunomodulator and binds to EGFL7. Parsatuzumab selectively blocks the interaction between EGFL7 and endothelial cells, potentially inhibiting vascular regrowth and reducing vascular endothelial growth factor (VEGF) inhibition .

HY-P9920A

Ramucirumab (anti-VEGFR)	VEGFR	Cancer
Ramucirumab (anti-VEGFR) is a human VEGFR-2 antagonist for the treatment of solid tumors. Ramucirumab (anti-VEGFR) is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D. Ramucirumab (anti-VEGFR) is also an angiogenesis inhibitor .

HY-P1663

ATWLPPR Peptide 1 Publications Verification	VEGFR	Others
ATWLPPR Peptide is a biological active peptide. (This peptide is a specific VEGFR2/KDR heptapeptide antagonist, it binds VEGFR2 (KDR/flk), completely inhibiting VEGF binding to KDR and preventing VEGF-induced angiogenesis in-vivo. It specifically inhibits human endothelial cell proliferation in-vitro and totally abolishes VEGF-induced angiogenesis in-vivo.)

HY-P3369

Gersizangitide AXT-107	VEGFR Tie Akt	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
Gersizangitide (AXT107) is an anti-angiogenic peptide consisting of 20 amino acids, derived from collagen IV. Gersizangitide is an inhibitor of *VEGF-A* and *VEGF-C* and an activator of Tie2. Gersizangitide can block *VEGF* receptor signaling, inhibit vascular leakage, neovascularization and inflammation. Gersizangitide can be used in the research of diseases related to ocular neovascularization and angiogenesis .

HY-147762

NRP1 antagonist 2	Complement System	Cancer
NRP1 antagonist 2 (Compound 1) is an NRP1 antagonist .

HY-128446

CAY10781	VEGFR	Neurological Disease
CAY10781 (Compound 11) is an inhibitor of the neuropilin-1 (NRP-1) and *VEGF-A* interaction. CAY10781 inhibits VEGF-A-induced phosphorylation of VEGFR2 in Catecholamine A-differentiated (CAD) cells ^{[1]< sup>.}

HY-157231A

HC-5404-Fu	PERK	Cancer
HC-5404-Fu is a PERK inhibitor with an antitumor activity. HC-5404-Fu inhibits endoplasmic reticulum stress response signalling. HC-5404-Fu sensitizes renal cell carcinoma cells to vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitors (TKIs). HC-5404-Fu is promising for research of renal cell carcinoma, gastric cancer, metastatic breast cancer, small cell lung cancer, and other solid tumors .

Cat. No.	Product Name

HY-L125

Anti-Pulmonary Fibrosis Compound Library

2,167 compounds

Pulmonary fibrosis (PF), also known as diffuse interstitial pulmonary fibrosis, is a very common end-stage manifestation of several diseases, including idiopathic pulmonary fibrosis (IPF), pulmonary hypertension, and scleroderma, characterised by excessive matrix deposition and destruction of the lung architecture, finally leading to respiratory insufficiency. PF has become a global disease with significantly increased incidence rate, and the most common form of pulmonary fibrosis is idiopathic pulmonary fibrosis (IPF).

Lung fibrosis is a complex disease, a multitude of signal factors and signaling pathways is disrupted in this complex disease, such as TGF-β, Wnt, VEGF and PI3K–Akt. MCE offers a unique collection of 2,167 compounds with identified and potential anti-pulmonary fibrosis activity. MCE Anti-Pulmonary Fibrosis Compound Library is a useful tool for anti-pulmonary fibrosis drugs screening and other related research.

HY-L088

Angiogenesis-Related Compound Library

2,734 compounds

Angiogenesis is the physiological process through which new blood vessels are formed from pre-existing vessels. It occurs in various physiological processes e.g. embryonic development, menstrual cycle, exercise and wound healing etc. Angiogenesis is regulated by both endogenous activators and inhibitors. Some key activators of angiogenesis include vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), angiogenin, TGF-β, etc. whereas angiogenesis inhibitors are angiostatin, endostatin, interferon, platelet factor 4, etc. The loss of balance between these opposing signals leads to life threatening diseases like cancer, cardiovascular and ischemic diseases etc. which are thus controlled by exogenous angiogenesis activators (for cardiovascular/ischemic disorders) and inhibitors (for cancer).

MCE offers a unique collection of 2,734 compounds with validated angiogenesis targets modulating properties. MCE angiogenesis-related compound library is an effective tool for angiogenesis research and discovery of angiogenesis-related drugs.

HY-L103

Anti-Colorectal Cancer Compound Library

2,049 compounds

Colorectal cancer (CRC), also known as bowel cancer, colon cancer, or rectal cancer, arises as adenocarcinoma from glandular epithelial cells of the large intestine comprised of the colon and rectum. The majority of cases of CRC are sporadic and result from risk factors, such as a sedentary lifestyle, obesity, processed diets, alcohol consumption and smoking. CRC is also a common preventable cancer.

Studies showed several cellular signaling pathways dysregulated in CRC, leading to the onset of malignant phenotypes. Therefore, it is necessary to analyze the signaling pathways involved in the occurrence and development of colorectal cancer to study the progression and drug treatment of colorectal cancer. Among them, Wnt/β-catenin, p53, TGF-β/SMAD, NF-κB, Notch, VEGF and other target genes and signaling pathways are the focus of research. MCE offers a unique collection of 2,049 compounds with identified and potential anti-colorectal cancer activity. MCE anti-colorectal cancer compound library is a useful tool for anti-colorectal cancer drugs screening and other related research.

Cat. No.	Product Name	Type

HY-126437

Poly-L-lysine hydrobromide (MW 30000-70000)

1 Publications Verification

Drug Delivery

Poly-L-lysine hydrobromide (MW 30000-70000) is a water-soluble synthetic polypeptide. Poly-L-lysine hydrobromide (MW 30000-70000) downregulates Bcl-2 and upregulates Bax and p53 proteins. Poly-L-lysine hydrobromide (MW 30000-70000) promotes Apoptosis and reduces VEGF expression. Poly-L-lysine hydrobromide (MW 30000-70000) shows anticancer activity against a variety of tumors. Poly-L-lysine hydrobromide (MW 30000-70000) can also be used as a coating material .

HY-172488A

DSPE-PEG3400-K237	Drug Delivery
DSPE-PEG3400-K237 is a PEG compound which composed of DSPE and a KDR targeting peptide (K237). K237 can functionally disrupt the interaction between VEGF and the KDR receptor and cause potent biological effects that include the inhibition of angiogenesis and tumor growth. DSPE-PEG3400-K237 can be used for drug delivery .

HY-172489

DSPE-PEG5000-K237	Drug Delivery
DSPE-PEG5000-K237 is a PEG compound which composed of DSPE and a KDR targeting peptide (K237). K237 can functionally disrupt the interaction between VEGF and the KDR receptor and cause potent biological effects that include the inhibition of angiogenesis and tumor growth. DSPE-PEG5000-K237 can be used for drug delivery .

HY-172488

DSPE-PEG2000-K237	Drug Delivery
DSPE-PEG2000-K237 is a PEG compound which composed of DSPE and a KDR targeting peptide (K237). K237 can functionally disrupt the interaction between VEGF and the KDR receptor and cause potent biological effects that include the inhibition of angiogenesis and tumor growth. DSPE-PEG2000-K237 can be used for drug delivery .

HY-172487

DSPE-PEG1000-K237	Drug Delivery
DSPE-PEG1000-K237 is a PEG compound which composed of DSPE and a KDR targeting peptide (K237). K237 can functionally disrupt the interaction between VEGF and the KDR receptor and cause potent biological effects that include the inhibition of angiogenesis and tumor growth. DSPE-PEG1000-K237 can be used for drug delivery .

Cat. No.	Product Name	Target	Research Area

HY-P5558

KLTWQELYQLKYKGI	VEGFR	Inflammation/Immunology
KLTWQELYQLKYKGI (QK) is a VEGF mimicking peptide, binds to the VEGF receptors and competes with VEGF. KLTWQELYQLKYKGI is active in gastric ulcer healing in rodents when administered either orally or systemically. KLTWQELYQLKYKGI shows the ability to induce capillary formation and organization in vitro .

HY-P5107

Low molecular weight protamine LMWP	VEGFR	Cancer
Low molecular weight protamine is a cell-penetrating peptide with vascular endothelial growth factor (VEGF) inhibitory activity. Low molecular weight protamine can inhibit tumor growth and is used in cancer research .

HY-P5133

Synstatin (92-119) SSTN92-119	Integrin	Cancer
Synstatin (92-119) is an anti-tumor agent that inhibits angiogenesis and cancer cell invasion. Synstatin (92-119) down-regulates integrin α?β3 and reduces the activation of angiogenic growth factors VEGF and FGF-2 .

HY-P1663

ATWLPPR Peptide 1 Publications Verification	VEGFR	Others
ATWLPPR Peptide is a biological active peptide. (This peptide is a specific VEGFR2/KDR heptapeptide antagonist, it binds VEGFR2 (KDR/flk), completely inhibiting VEGF binding to KDR and preventing VEGF-induced angiogenesis in-vivo. It specifically inhibits human endothelial cell proliferation in-vitro and totally abolishes VEGF-induced angiogenesis in-vivo.)

HY-P3369

Gersizangitide AXT-107	VEGFR Tie Akt	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
Gersizangitide (AXT107) is an anti-angiogenic peptide consisting of 20 amino acids, derived from collagen IV. Gersizangitide is an inhibitor of *VEGF-A* and *VEGF-C* and an activator of Tie2. Gersizangitide can block *VEGF* receptor signaling, inhibit vascular leakage, neovascularization and inflammation. Gersizangitide can be used in the research of diseases related to ocular neovascularization and angiogenesis .

HY-P4253A

Arginyl-Glutamine TFA	VEGFR	Cardiovascular Disease
Arginyl-Glutamine TFA is a dipeptide that can decrease *VEGF* levels and inhibit retinal neovascularization in a mouse model of oxygen-induced retinopathy .

HY-P10521

Apolipoprotein KV domain (67-77)	VEGFR	Cancer
Apolipoprotein KV domain (67-77) is an 11-amino acid peptide identified from the KV domain of human apolipoprotein a (ApoA) with antiangiogenic and antitumor activities. Apolipoprotein KV domain (67-77) targets the angiogenic c-Src/ERK pathway by blocking activation signals received from vascular endothelial growth factor (VEGF). Apolipoprotein KV domain (67-77) can be used in cancer research .

HY-P10550

VGB4	VEGFR	Cancer
VGB4 is a *VEGF-A* and *VEGF-B* antagonist peptide that duplicates two binding domains of *VEGF-B* (loop 1 and loop3) and are linked together by the receptor-binding domain of *VEGF-A* (loop3). VGB4 has significant anti-angiogenic and anti-tumor activities and can regulate tumor growth and metastasis through multiple mechanisms. VGB4 could be used in anti-tumor research .

HY-P4253

Arginyl-Glutamine	VEGFR	Cardiovascular Disease
Arginyl-Glutamine is a dipeptide that can decrease *VEGF* levels and inhibit retinal neovascularization in a mouse model of oxygen-induced retinopathy .

HY-P5527F

FAM-CSKtide	Peptides	Others
FAM-CSKtide is a biological active peptide. (This is a FAM labeled peptide substrate (Abs/Em = 494/521 nm) for C-terminal Src kinase (Csk) and many other kinases such as Axl, cKit, ERBB4, Fes, Flt3, IGF-1 R, MET, MUSK, PYK2, Ret, TIE2, TrkA, VEGF-R1 and VEGF-R2.)

HY-P5438

Srctide	Btk c-Kit FAK FLT3 Insulin Receptor	Others
Srctide is a biological active peptide. (This is a peptide substrate for many protein kinases, such as Blk, BTK, cKit, EPHA1, EPHB2, EPHB3, ERBB4, FAK, Flt3, IGF-1R, ITK, Lck, MET, MUSK, Ret, Src, TIE2, TrkB, VEGF-R1 (Flt-1) and VEGF-R2 (KDR).)

HY-P3999

Fibulostatin 6.2	Peptides	Cardiovascular Disease
Fibulostatin 6.2 is an anti-angiogenic peptide that can inhibit migration of human umbilical vein endothelial cells in vitro .

HY-P3995

Scospondistatin	VEGFR	Cardiovascular Disease
Scospondistatin is an anti-angiogenic peptide that can inhibit proliferation and migration of human umbilical vein endothelial cells in vitro .

HY-13718

Oglufanide H-Glu-Trp-OH; L-Glutamyl-L-tryptophan	VEGFR HCV Endogenous Metabolite	Infection Cardiovascular Disease Inflammation/Immunology Cancer
Oglufanide (H-Glu-Trp-OH) is a dipeptide immunomodulator isolated from calf thymus. Oglufanide inhibits vascular endothelial growth factor (VEGF). Oglufanide can stimulate the immune response to hepatitic C virus (HCV) and intracellular bacterial infections. Oglufanide shows antitumor and anti-angiogenesis activities .

HY-P10301

CXCL9(74-103)	CXCR	Cancer
CXCL9(74-103) is a derivative peptide of CXCL9 that has a high affinity for glycosaminoglycans (GAGs) and can bind to GAGs. CXCL9(74-103) possesses anti-angiogenic properties, capable of reducing EGF, VEGF165, and FGF-2-mediated angiogenesis processes in vitro, without exhibiting cytotoxicity .

HY-P10831

GNQWFI	VEGFR	Cardiovascular Disease Cancer
GNQWFI, an anti-Flt1 peptide, is a VEGFR1-specific antagonist. GNQWFI blocks the interaction of VEGFR1 with various VEGFR1 ligands, such as VEGFA, VEGFB, and placental growth factor (PIGF) and inhibits VEGF-induced endothelial cell migration and tube formation. GNQWFI is promising for research of cancer, asthma, and other ocular diseases .

HY-P10426

cyclo(CLLFVY)	HIF/HIF Prolyl-Hydroxylase VEGFR	Cancer
cyclo(CLLFVY) is an inhibitor for hypoxia inducible factor-1 (HIF-1), with IC₅₀ of 19 μM (in U2OS) and 16 μM (in MCF-7). cyclo(CLLFVY) binds to the PAS-B domain of HIF-1α, inhibits HIF-1 dimerization and transcriptional activity. cyclo(CLLFVY) downregulates the expression of hypoxia response genes, such as VEGF and CAIX, exhibits antitumor against the HIF-1 associated cancers .

HY-P1435

NoxA1ds	NADPH Oxidase	Cardiovascular Disease Cancer
NoxA1ds is a potent and highly selective NADPH oxidase 1 (NOX1) inhibitor (IC₅₀=20 nM). NoxA1ds inhibits NOX1-derived O ^2- production in HT-29 human colon cancer cells. NoxA1ds attenuates VEGF-induced human pulmonary artery endothelial cell migration under hypoxic conditions in vitro. NoxA1ds can be used in the study of hypertension, atherosclerosis and tumors .

HY-P1435A

NoxA1ds TFA	NADPH Oxidase	Cardiovascular Disease Cancer
NoxA1ds TFA is a potent and highly selective NADPH oxidase 1 (NOX1) inhibitor (IC₅₀=20 nM). NoxA1ds TFA inhibits NOX1-derived O ^2- production in HT-29 human colon cancer cells. NoxA1ds TFA attenuates VEGF-induced human pulmonary artery endothelial cell migration under hypoxic conditions in vitro. NoxA1ds TFA can be used in the study of hypertension, atherosclerosis and tumors .

HY-P2813

Hirudin 1 Publications Verification	Thrombin Apoptosis	Cardiovascular Disease Cancer
Hirudin is a thrombin inhibitor with blood anticoagulant property. Hirudin has potent anti-thrombotic, wound repair, anti-fibrosis, anti-tumor and anti-hyperuricemia effects. Hirudin also affects diabetic complications, cerebral hemorrhage, and others .

HY-16050R

Plitidepsin (Standard) Aplidine (Standard); PM90001 (Standard)	Reference Standards DNA/RNA Synthesis SARS-CoV	Infection Cancer
Plitidepsin (Standard) is the analytical standard of Plitidepsin. This product is intended for research and analytical applications. Plitidepsin (Aplidine) is a potent anti-cancer agent by targeting eEF1A2 ( K_D=80 nM) . Plitidepsin possesses antiviral activity and is against SARS-CoV-2 with an IC₉₀ of 0.88 nM. Plitidepsin is usually used for multiple myeloma and advanced cancer research, and has the potential for COVID-19 research .

HY-16050

Plitidepsin 3 Publications Verification Aplidine; PM90001	DNA/RNA Synthesis SARS-CoV	Infection Cancer
Plitidepsin (Aplidine) is a potent anti-cancer agent by targeting eEF1A2 ( K_D=80 nM) . Plitidepsin possesses antiviral activity and is against SARS-CoV-2 with an IC₉₀ of 0.88 nM. Plitidepsin is usually used for multiple myeloma and advanced cancer research, and has the potential for COVID-19 research .

HY-P10971

Nef-M1	CXCR Apoptosis VEGFR GSK-3 Cadherin Caspase	Cancer
Nef-M1 (Nef-Motif-1) is an antagonist peptide targeting CXCR4 and an apoptosis inducer derived from a myristoylated protein encoded by the nef gene in HIV. Nef-M1 inhibits tumor angiogenesis and epithelial-mesenchymal transition (EMT). Nef-M1 activates the apoptosis pathway by increasing the level of caspase-3 in cancer cells. Nef-M1 simultaneously inhibits *VEGF-A, p-GSK-3β* and vimentin, and enhances E-cadherin, thereby inhibiting angiogenesis and EMT processes. Nef-M1 can be used in the study of colorectal cancer and breast cancer .

Cat. No.	Product Name	Target	Research Area

HY-P990148

*Anti-Mouse VEGF-A Antibody (2G11-2A05)*	VEGFR	Cancer
Anti-Mouse VEGF-A Antibody (2G11-2A05) is a rat-derived anti-VEGF-A IgG2a, κ type antibody inhibitor, binding to mouse *VEGF-A* with high affinity. Anti-Mouse VEGF-A Antibody (2G11-2A05) shows good anti-tumor effect in gastric cancer xenograft models .

HY-P9951A

*Ranibizumab (anti-VEGF)* 1 Publications Verification RG-6321 (anti-VEGF)	VEGFR	Cardiovascular Disease
Ranibizumab (RG-6321) (anti-VEGF) is a humanized anti-VEGF monoclonal antibody fragment and can recognize all VEGF-A isoforms (VEGF110, VEGF121, and VEGF165) . Ranibizumab (anti-VEGF) slows vision loss in vivo and is used for wet age-related macular degeneration (AMD) research .

HY-P9906A

Bevacizumab (PBS) Maximum Cited Publications 36 Publications Verification Anti-Human VEGF, Humanized Antibody (PBS)	VEGFR	Cancer
Bevacizumab, a humanized IgG1 monoclonal antibody, specifically binds to all *VEGF-A* isoforms with high affinity .

HY-108801A

*Aflibercept (VEGF* Trap)** 1 Publications Verification	VEGFR	Cardiovascular Disease Metabolic Disease Cancer
Aflibercept (VEGF Trap) is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease .

HY-P9906

Bevacizumab Maximum Cited Publications 36 Publications Verification Anti-Human VEGF, Humanized Antibody	VEGFR	Cancer
Bevacizumab, a humanized IgG1 monoclonal antibody, specifically binds to all *VEGF-A* isoforms with high affinity.

HY-P99905

Efdamrofusp alfa 1 Publications Verification	VEGFR	Cardiovascular Disease Neurological Disease
Efdamrofusp alfa is a bispecific fusion protein. Efdamrofusp alfa is capable of neutralizing both VEGF isoforms and C3b/C4b. Efdamrofusp alfa can be used for the research of neovascular age-related macular degeneration (nAMD) and other complement-related ocular conditions .

HY-P99215

Parsatuzumab Anti-EGFL7; RG 7414	VEGFR	Cancer
Parsatuzumab (Anti-EGFL7; RG 7414) is a humanized monoclonal antibody, acts as an immunomodulator and binds to EGFL7. Parsatuzumab selectively blocks the interaction between EGFL7 and endothelial cells, potentially inhibiting vascular regrowth and reducing vascular endothelial growth factor (VEGF) inhibition .

HY-108801

Aflibercept VEGF Trap; VEGF-TRAPR1R2; VEGF-trapR1	VEGFR	Cardiovascular Disease Metabolic Disease Cancer
Aflibercept (VEGF Trap) is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease .

HY-P990538

*Anti-VEGF* Antibody**	Inhibitory Antibodies	Inflammation/Immunology

HY-P991384

DX-2240	Tie	Cancer
DX-2240 is a human monoclonal antibody (mAb) targeting TIE1. DX-2240 inhibits tumor growth and sensitizes tumor vasculature to anti-angiogenic agents (VEGF pathway inhibitors) .

HY-P9920A

Ramucirumab (anti-VEGFR)	VEGFR	Cancer
Ramucirumab (anti-VEGFR) is a human VEGFR-2 antagonist for the treatment of solid tumors. Ramucirumab (anti-VEGFR) is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D. Ramucirumab (anti-VEGFR) is also an angiogenesis inhibitor .

HY-P99675

Ivonescimab AK112	PD-1/PD-L1 VEGFR	Cancer
Ivonescimab (AK112) is a *PD-1/VEGF* bispecific antibody. Ivonescimab competitively inhibiting PD-1/PD-L1 interaction, reversing the immunosuppression mediated by it, and blocks the binding of VEGF-A to VEGFR2, inhibiting tumour angiogenesis in the tumour microenvironment. Ivonescimab also has significantly anticancer activity against EGFR-mutated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCL) .

HY-P991329

ASP-1948	Complement System	Cancer
ASP-1948 is a human monoclonal antibody (mAb) targeting *NRP1/VEGF165R/CD34*. ASP-1948 reverses the suppressive effects of regulatory T cells. ASP-1948 can be used in solid tumors research .

HY-P990082

Suvemcitug	VEGFR	Cancer
Suvemcitug is a humanized IgG1κ antibody targeting *VEGF* derived from the African hare (Oryctolagus cuniculus) .

HY-P991625

VX70	VEGFR	Cancer
VX70 is a humanized monoclonal antibody inhibitor targeting *VEGF-A*. VX70 can be used for cancers research .

HY-P991097

PM-8002 BNT-327	VEGFR PD-1/PD-L1	Cancer
PM-8002 is a bispecific antibody that targets both PD-L1 and *VEGF-A*. PM-8002 can be used for the study of solid tumors .

HY-P9973

Brolucizumab DLX1008; ESBA 1008; RTH258	VEGFR	Cancer
Brolucizumab (DLX1008) is a single-chain anti-VEGF-A antibody fragment with low picomolar affinity (K_D=1.05 pM). Brolucizumab can be used for the research of cancer .

HY-P99852

Dilpacimab ABT165; PR1283233	VEGFR	Cancer
Dilpacimab (ABT165) is a potent dual-variable domain immunoglobulin, targets both delta-like ligand 4 (DLL4) and *VEGF* pathways.. Dilpacimab can be used in research of cancer .

HY-P99330

Vanucizumab Anti-Human VEGFA Recombinant Antibody; RO5520985	VEGFR Tie	Cancer
Vanucizumab is a first-in-class, bispecific IgG1-like monoclonal antibody that simultaneously blocks *VEGF-A* and angiopoietin-2 (Ang-2) from interacting with their receptors. Vanucizumab has antiangiogenic and anticancer effects .

HY-P99830

Conbercept KH902	VEGFR	Cardiovascular Disease
Conbercept (KH902) is a recombinant fusion protein composed of VEGFR-1 (second domain) and VEGFR-2 (third and fourth domains) regions fused to human IgG1 Fc. Conbercept is a vascular endothelial growth factor (VEGF) inhibitor .

HY-P991415

ASKG-712 AM712	VEGFR Tie	Others
ASKG-712 (AM712) is a recombinant anti-VEGF humanized monoclonal antibody and Ang-2 antagonist peptide fusion protein. ASKG-712 can be used in Wet age-related macular degeneration and Diabetic macular oedema research .

HY-P99768

Olinvacimab TTAC-0001	VEGFR	Cancer
Olinvacimab (TTAC-0001) is a fully human anti-VEGFR2 monoclonal antibody. Olinvacimab inhibits VEGF binds to KDR with a K_d value of 0.23 nM. Olinvacimab has antiangiogenic activity. Olinvacimab can be used for the research of recurrent glioblastoma and breast cancer .

HY-145633

Sozinibercept OPT 302; VGX-300	VEGFR	Cardiovascular Disease
Sozinibercept (OPT 302; VGX-300) is a soluble form of VEGFR-3, potently inhibits the activity of *VEGF-C/D*, which are the proangiogenic factors, inhibiting angiogenesis and vascular leakage. Sozinibercept also inhibits diabetic retinal edema in rats .

HY-P991141

Inlecitug	VEGFR	Cancer
Inlecitug is a chimeric monoclonal antibody targeting human KDR (kinase insert domain receptor). Inlecitug specifically binds to KDR, blocking the binding of vascular endothelial growth factor (VEGF) to KDR and inhibiting angiogenesis, thus exerting antitumor activity. Inlecitug is promising for research of cancers .

HY-P99377

Navicixizumab OMP-305B83; Anti-DLL4 Reference Antibody (navicixizumab)	Notch	Cancer
Navicixizumab (OMP-305B83) is a bispecific anti-VEGF and anti-DLL4 inhibitory antibody. Navicixizumab can combine with Paclitaxel (HY-B0015) for cancer research. Navicixizumab can be used in the research of ovarian, primary peritoneal, or fallopian tube cancer .

HY-108798

Ziv-aflibercept	VEGFR	Cardiovascular Disease Cancer
Ziv-aflibercept is a soluble inhibitor of vascular endothelial growth factor (VEGF). Ziv-aflibercept is an adaptive variant of Aflibercept (HY-108801), Ziv-aflibercept has a low PH value and high osmotic pressure when compared to Aflibercept. Ziv-aflibercept has potential applications in metastatic colorectal carcinoma and retinal diseases .

HY-P99590

Sotatercept ACE-011	TGF-β Receptor	Cardiovascular Disease Inflammation/Immunology Cancer
Sotatercept (ACE-011) is a soluble activin receptor 2A (ACVR2A) type IgG Fc fusion protein. Sotatercept combines activin and growth differentiation factor to try to restore the balance between growth promotion and growth inhibition signal pathways. Sotatercept has potential application in pulmonary arterial hypertension, anemia, bone loss, erythropoiesis, multiple myeloma (MM) osteolytic lesions .

HY-P990106

Anti-Mouse VEGFR-2 Antibody (DC101)	VEGFR Apoptosis	Inflammation/Immunology Cancer
Anti-Mouse VEGFR-2 Antibody (DC101) is a rat anti-mouse VEGFR2 monoclonal antibody. Anti-Mouse VEGFR-2 Antibody (DC101) inhibits tumor angiogenesis by blocking the binding of VEGF and VEGFR2. Anti-Mouse VEGFR-2 Antibody (DC101) promotes immune cell infiltration and induces tumor cell apoptosis. Anti-Mouse VEGFR-2 Antibody (DC101) can be used for research on various types of cancer such as melanoma, lung cancer and breast cancer .

HY-P99116

Faricimab RG7716	VEGFR	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
Faricimab, an overall good safety and tolerability profile, is a bispecific antibody targeting Angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A). Faricimab prevents retinal vascular leakage, cell death and inflammation in retinal ischemia/reperfusion (I/R) injury and sCNV mouse models. Faricimab demonstrates statistically superior visual acuity gains versus Ranibizumab (HY-P9951). Faricimab can be used for retinal diseases, such as age-related macular degeneration (w-AMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO) .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-18963

Lavendustin A RG-14355	Structural Classification Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Source classification Phenols Polyphenols Disease Research Fields Cancer	EGFR
Lavendustin A (RG-14355) is a potent, selective and ATP-competitive inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, with an IC₅₀ of 11 nM. Lavendustin A does not inhibit protein kinase A or C. Lavendustin A can suppress VEGF-induced angiogenesis .

HY-N2666

5α-Hydroxycostic acid	Other Terpenoids Classification of Application Fields Terpenoids Source classification Erythrina burttii Baker f. Plants Compositae Disease Research Fields Cancer	VEGFR
5α-Hydroxycostic acid, a eudesmane-type sesquiterpene, is isolated from the herb Laggera alata. 5α-Hydroxycostic acid inhibits angiogenesis and suppresses breast cancer cell migration through regulating *VEGF/VEGFR2* and Ang2/Tie2 pathways .

HY-110066

(Z)-Guggulsterone 5+ Cited Publications	Structural Classification Classification of Application Fields Commiphora myrrha (Nees) Engl. Source classification Plants Burseraceae Disease Research Fields Steroids Cancer	Apoptosis VEGFR Akt Angiotensin-converting Enzyme (ACE) SARS-CoV FXR
(Z)-Guggulsterone, a constituent of Indian Ayurvedic medicinal plant Commiphora mukul, inhibits the growth of human prostate cancer cells by causing apoptosis. (Z)-Guggulsterone inhibits angiogenesis by suppressing the *VEGF–VEGF-R2–Akt* signaling axis . (Z)-Guggulsterone is also a potent FXR antagonist. (Z)-Guggulsterone reduces ACE2 expression and SARS-CoV-2 infection .

HY-N0545

Taurocholic acid sodium 20+ Cited Publications Sodium taurocholate; N-Choloyltaurine sodium	Structural Classification Classification of Application Fields Source classification Endogenous metabolite Inflammation/Immunology Disease Research Fields Steroids	VEGFR Endogenous Metabolite
Taurocholic acid sodium (Sodium taurocholate) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid sodium has immunoregulation effect .

HY-B0239

Chloramphenicol 5+ Cited Publications	Structural Classification Classification of Application Fields Anti-aging Source classification Antibacterial Disease Research Endogenous metabolite Other Antibiotics Infection Human Gut Microbiota Metabolites Plant Cell Culture Microorganisms Antibiotics Resistance Selection Animal Husbandry Anticancer Disease Research Fields Cancer	Antibiotic Bacterial HIF/HIF Prolyl-Hydroxylase VEGFR Autophagy Apoptosis Beclin1 JNK Akt MMP
Chloramphenicol is an orally active, potent and broad-spectrum antibiotic. Chloramphenicol shows antibacterial activity. Chloramphenicol represses the oxygen-labile transcription factor and hypoxia inducible factor-1 alpha (HIF-1α) in hypoxic A549 and H1299 cells. Chloramphenicol suppresses the mRNA levels of vascular endothelial growth factor (VEGF) and glucose transporter 1, eventually decreasing VEGF release. Chloramphenicol can be used for anaerobic infections and lung cancer research .

HY-N0135

Tanshinone IIA Maximum Cited Publications 27 Publications Verification Dan Shen ketone	Quinones Structural Classification Classification of Application Fields Terpenoids Labiatae Samanea saman (Jacq.) Merr. Source classification Diterpenoids Plants Naphthalene Quinones Disease Research Fields Cancer	VEGFR
Tanshinone IIA (Tan IIA) is one of the main compositions in the root of Salvia miltiorrhiza Bunge. Tanshinone IIA may suppress angiogenesis by targeting the protein kinase domains of *VEGF/VEGFR2*.

HY-N7177

Hydroxytanshinone IIA	Quinones Classification of Application Fields Labiatae Source classification Samanea saman (Jacq.) Merr. Plants Naphthalene Quinones Disease Research Fields Cancer	Drug Metabolite VEGFR
Hydroxytanshinone IIA is a hydroxylated metabolite of Tanshinone IIA. Tanshinone IIA may suppress angiogenesis by targeting the protein kinase domains of *VEGF/VEGFR2* .

HY-18963R

Lavendustin A (Standard) RG-14355 (Standard)	Structural Classification Microorganisms Ketones, Aldehydes, Acids Source classification Phenols Polyphenols	Reference Standards EGFR
Lavendustin A (Standard) is the analytical standard of Lavendustin A. This product is intended for research and analytical applications. Lavendustin A (RG-14355) is a potent, selective and ATP-competitive inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, with an IC50 of 11 nM. Lavendustin A does not inhibit protein kinase A or C. Lavendustin A can suppress VEGF-induced angiogenesis[1][2].

HY-N15264

Azaspirene (-)-Azaspirene	Structural Classification Natural Products Microorganisms Source classification	VEGFR Raf
Azaspirene ((-)-Azaspirene) is an angiogenesis and Raf-1 activation inhibitor isolated from the fungus Neosartorya sp. Azaspirene inhibits vascular endothelial growth factor (VEGF)-induced human umbilical vein endothelial cell (HUVEC) migration and Raf-1 activation, but has no effect on the activation of kinase insert domain-containing receptor/fetal liver kinase 1 (VEGF receptor 2) .

HY-110066R

(Z)-Guggulsterone (Standard)	Structural Classification Commiphora myrrha (Nees) Engl. Source classification Plants Burseraceae Steroids	Reference Standards Apoptosis VEGFR Akt Angiotensin-converting Enzyme (ACE) SARS-CoV FXR
(Z)-Guggulsterone (Standard) is the analytical standard of (Z)-Guggulsterone. This product is intended for research and analytical applications. (Z)-Guggulsterone, a constituent of Indian Ayurvedic medicinal plant Commiphora mukul, inhibits the growth of human prostate cancer cells by causing apoptosis. (Z)-Guggulsterone inhibits angiogenesis by suppressing the VEGF–VEGF-R2–Akt signaling axis . (Z)-Guggulsterone is also a potent FXR antagonist. (Z)-Guggulsterone reduces ACE2 expression and SARS-CoV-2 infection .

HY-B1788

Taurocholic acid 20+ Cited Publications N-Choloyltaurine	Structural Classification Human Gut Microbiota Metabolites Classification of Application Fields Source classification Endogenous metabolite Inflammation/Immunology Disease Research Fields Steroids	Endogenous Metabolite
Taurocholic acid (N-Choloyltaurine) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid has immunoregulation effect .

HY-B0239R

Chloramphenicol (Standard)	Structural Classification Source classification Antibacterial Disease Research Endogenous metabolite Other Antibiotics Human Gut Microbiota Metabolites Plant Cell Culture Microorganisms Antibiotics Resistance Selection Animal Husbandry Anticancer	Reference Standards Antibiotic Bacterial HIF/HIF Prolyl-Hydroxylase VEGFR Autophagy Apoptosis Beclin1 JNK Akt MMP
Chloramphenicol (Standard) is the analytical standard of Chloramphenicol. This product is intended for research and analytical applications. Chloramphenicol is an orally active, potent and broad-spectrum antibiotic. Chloramphenicol shows antibacterial activity. Chloramphenicol represses the oxygen-labile transcription factor and hypoxia inducible factor-1 alpha (HIF-1α) in hypoxic A549 and H1299 cells. Chloramphenicol suppresses the mRNA levels of vascular endothelial growth factor (VEGF) and glucose transporter 1, eventually decreasing VEGF release. Chloramphenicol can be used for anaerobic infections and lung cancer research .

HY-N2187

Deoxyshikonin 2 Publications Verification	Infection Cardiovascular Disease Quinones Structural Classification Classification of Application Fields Plants Naphthalene Quinones Boraginaceae Disease Research Fields Arnebia euchroma (Royle) Johnst.	Bacterial HIF/HIF Prolyl-Hydroxylase PI3K Apoptosis
Deoxyshikonin increases the expression of *VEGF-C* and *VEGF-A* mRNA in HMVEC-dLy, promotes HIF-1α and HIF-1β subunit interaction and binds to specific DNA sequences targeted by HIF. Deoxyshikonin inhibited colorectal cancer (CRC) through the PI3K/Akt/mTOR pathway. Deoxyshikonin has proangiogenesis effect and antitumor activity. Deoxyshikonin is an antibacterial agent against methicillin-resistant S. aureus (MRSA) and S. pneumonia (MIC=17 μg/mL) .

HY-12686

5Z-7-Oxozeaenol 20+ Cited Publications FR148083; L783279; LL-Z 1640-2	Structural Classification Natural Products Monophenols Microorganisms Classification of Application Fields Source classification Phenols Inflammation/Immunology Disease Research Fields	MAP3K VEGFR Antibiotic
5Z-7-Oxozeaenol is a natural anti-protozoan compound from fungal origin, acting as a potent irreversible and selective inhibitor of TAK1 and *VEGF-R2, with IC₅₀*s of 8 nM and 52 nM, respectively.

HY-N0896

Inulicin 1 Publications Verification 1-O-Acetylbritannilactone	Phyllodium pulchellum (L.) Desv. Structural Classification Classification of Application Fields Terpenoids Sesquiterpenes Source classification Plants Compositae Inflammation/Immunology Disease Research Fields	NF-κB COX
Inulicin (1-O-Acetylbritannilactone) is an active compound that inhibits VEGF-mediated activation of Src and FAK. Inulicin (1-O-Acetylbritannilactone) inhibits LPS-induced PGE₂ production and COX-2 expression, and NF-κB activation and translocation.

HY-N0545R

Taurocholic acid sodium (Standard) 5+ Cited Publications Sodium taurocholate (Standard); N-Choloyltaurine sodium (Standard)	Structural Classification Classification of Application Fields Source classification Endogenous metabolite Inflammation/Immunology Disease Research Fields Steroids	Reference Standards VEGFR Endogenous Metabolite
Taurocholic acid (sodium) (Standard) is the analytical standard of Taurocholic acid (sodium). This product is intended for research and analytical applications. Taurocholic acid sodium (Sodium taurocholate) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid sodium has immunoregulation effect .

HY-B1788R

Taurocholic acid (Standard) Taurocholic Acid (Standard)	Structural Classification Human Gut Microbiota Metabolites Microorganisms Source classification Endogenous metabolite Steroids	Reference Standards Endogenous Metabolite
Taurocholic acid (Standard) is the analytical standard of Taurocholic acid. This product is intended for research and analytical applications. Taurocholic acid (N-Choloyltaurine) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid has immunoregulation effect .

HY-N0135R

Tanshinone IIA (Standard) Dan Shen ketone (Standard)	Quinones Structural Classification Terpenoids Labiatae Samanea saman (Jacq.) Merr. Source classification Diterpenoids Plants Naphthalene Quinones	Reference Standards VEGFR
Tanshinone IIA (Standard) is the analytical standard of Tanshinone IIA. This product is intended for research and analytical applications. Tanshinone IIA (Tan IIA) is one of the main compositions in the root of Salvia miltiorrhiza Bunge. Tanshinone IIA may suppress angiogenesis by targeting the protein kinase domains of VEGF/VEGFR2.

HY-119767

Jolkinolide A	Structural Classification Euphorbia fischeriana Steud. Terpenoids Source classification Diterpenoids Euphorbiaceae Plants	VEGFR Apoptosis
Jolkinolide A is a diterpenoid, can be extracted from the roots of Euphorbia fischeriana Steud. Jolkinolide A exhibits anti-tumor activity, by affecting on angiogenesis of tumor tissues. Jolkinolide A significantly inhibits the Akt-STAT3-mTOR signaling pathway and reduces the expression of *VEGF* in A549 cells .

HY-114535

Jaceidin	Flavonoids Erythrina suberosa Roxb. Source classification Plants Compositae Isoflavones	EGFR
Jaceidin is a promising lead molecule for potent VEGFR inhibitor with excellent membrane permeability and oral bioavailability. Jaceidin exhibits anti-tumor activities .

HY-13718

Oglufanide H-Glu-Trp-OH; L-Glutamyl-L-tryptophan	Cardiovascular Disease Structural Classification Classification of Application Fields Animals Ketones, Aldehydes, Acids Source classification Endogenous metabolite Inflammation/Immunology Disease Research Fields	VEGFR HCV Endogenous Metabolite
Oglufanide (H-Glu-Trp-OH) is a dipeptide immunomodulator isolated from calf thymus. Oglufanide inhibits vascular endothelial growth factor (VEGF). Oglufanide can stimulate the immune response to hepatitic C virus (HCV) and intracellular bacterial infections. Oglufanide shows antitumor and anti-angiogenesis activities .

HY-N5136

25(R,S)-Ruscogenin	Liliaceae Microorganisms Classification of Application Fields Source classification Liriope platyphylla Wang et Tang Plants Disease Research Fields Steroids Cancer	Apoptosis PI3K Akt mTOR
Ruscogenin suppresses HCC metastasis by reducing the expression of MMP-2, MMP-9, uPA, VEGF and HIF-1α via regulating the PI3K/Akt/mTOR signaling pathway . And Ruscogenin alleviates LPS-induced pulmonary endothelial cell apoptosis by su

HY-N7830

7α,15-Dihydroxydehydroabietic acid	Structural Classification Terpenoids Labiatae Source classification Diterpenoids Plants Achillea clypeolata Sm.	ERK
7α,15-Dihydroxydehydroabietic acid is a natural abietane-type diterpenoid with antiangiogenic effects .

HY-134000

Emodic acid NSC624610	Quinones Structural Classification Human Gut Microbiota Metabolites Microorganisms Leguminosae Cercis chinensis Bunge Anthraquinones Source classification Plants Endogenous metabolite	p38 MAPK NF-κB ERK JNK VEGFR MMP
Emodic acid (NSC624610) is an anthraquinone compound isolated from A. microcarpus, which can inhibit the proliferation of cancer cells by inhibiting the activity of NF-κB. Emodic acid can also inhibit the phosphorylation of p38, ERK and JNK, the secretion of tumor-promoting cytokines IL-1β and IL-6, and the expression of *VEGF* and MMP, thereby inhibiting the invasion and migration potential of cancer cells .

HY-N1435

Oroxin B 4 Publications Verification	Structural Classification Flavonoids Classification of Application Fields Flavones Source classification Phenols Polyphenols Bignoniaceae Plants Oroxylum indicum (Linn.) Bentham ex Kurz Disease Research Fields Cancer	Apoptosis PI3K PTEN Autophagy
Oroxin B (OB) is a flavonoid isolated from traditional Chinese herbal medicine Oroxylum indicum (L.) Vent. Oroxin B (OB) possesses obvious inhibitory effect and induces early apoptosis rather than late apoptosis on liver cancer cells through upregulation of PTEN, down regulation of COX-2, VEGF, PI3K, and p-AKT . Oroxin B (OB) selectively induces tumor-suppressive ER stress in malignant lymphoma cells .

HY-B2163

Astaxanthin 10+ Cited Publications	Cardiovascular Disease Structural Classification Classification of Application Fields Anti-aging Source classification Whitening Agent Research on Agricultural Breeding Food Research Agricultural Research Microorganisms Sunscreen Terpenoids Pigments Diterpenoids Cosmetic Research Disease Research Fields	PPAR Reactive Oxygen Species (ROS) STAT NF-κB Apoptosis
Astaxanthin, the red dietary carotenoid, is an orally effective and potent antioxidant. Astaxanthin inhibits NF-κB and down-regulates *VEGF* in blood glucose. Astaxanthin exerts anti-cancer cell proliferation, increases apoptosis, impairs migration and invasion by activating PPARγ and reducing the expression of STAT3. Astaxanthin also has neuroprotective and anti-inflammatory activity and can be used in studies of cancer, diabetic retinopathy, cardiovascular disease, and in the coloring of animal feed .

HY-N2199

Sotetsuflavone	Structural Classification Flavonoids Classification of Application Fields Source classification Phenols Polyphenols Selaginellaceae Plants Biflavones Selaginella tamariscina (P. Beauv.) Spring Disease Research Fields Cancer	Apoptosis Autophagy
Sotetsuflavone is a flavonoid that can be isolated from Cycas revolute. Sotetsuflavone inhibits migration and invasion of A549 cells by reversing EMT, and induces cell apoptosis and autophagy. Sotetsuflavone inhibits HIF-1α, VEGF, angiostatin, MMP-9, and MMP-13 expression in A549 cells. Sotetsuflavone also protects mice against Crohn's disease (CD)-like colitis. Sotetsuflavone can be used for research of NSCLC .

HY-N10330

7-Hydroxyneolamellarin A	Structural Classification Animals Source classification Phenols	HIF/HIF Prolyl-Hydroxylase VEGFR
7-Hydroxyneolamellarin A is a natural product that could be derived from sponge Dendrilla nigra. 7-Hydroxyneolamellarin A is a potent hypoxia-inducible factor-1α (HIF-1α) inhibitor. 7-Hydroxyneolamellarin A attenuates the accumulation of hypoxia-inducible factor-1α (HIF-1α) protein and inhibits vascular epidermal growth factor (VEGF) transcriptional activity. 7-Hydroxyneolamellarin A can be used in research of cancer .

HY-N0876

Arenobufagin 3 Publications Verification	Structural Classification Animals Classification of Application Fields Source classification Disease Research Fields Steroids Cancer	Apoptosis Autophagy PI3K Akt mTOR PARP Caspase Atg8/LC3
Arenobufagin is a natural bufadienolide that can be extracted from toad venom. Arenobufagin can induce apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K/Akt/mTOR pathway. Arenobufagin has potent antineoplastic activity against HCC HepG2 cells as well as corresponding multidrug-resistant HepG2/ADM cells. Arenobufagin can inhibit *VEGF*-mediated angiogenesis through suppression of VEGFR-2 signaling pathway .

HY-N5112B

β,β-Dimethylacrylshikonin 1 Publications Verification Isoarnebin I	Quinones Structural Classification Classification of Application Fields Source classification Phenols Polyphenols Plants Lithospermum erythrorhizon Sieb. et Zucc. Naphthalene Quinones Boraginaceae Disease Research Fields Cancer	HIF/HIF Prolyl-Hydroxylase Apoptosis Notch NO Synthase Bcl-2 Family
β,β-Dimethylacrylshikonin (Isoarnebin I) is a naphthoquinone derivative that can be isolated from Lithospermum erythrorhizon Sieb. et Zucc. β,β-Dimethylacrylshikonin promotes angiogenesis by inducing eNOS, *VEGF* and HIF-1α expression through the PI3K-dependent pathway. β,β-Dimethylacrylshikonin inhibits Notch-1 activation. β,β-Dimethylacrylshikonin inhibtis tumor cell proliferation, induces tumor cell apoptosis, and inhibits tumor growth .

HY-N1435R

Oroxin B (Standard)	Structural Classification Flavonoids Flavones Source classification Phenols Polyphenols Bignoniaceae Plants Oroxylum indicum (Linn.) Bentham ex Kurz	Reference Standards Apoptosis PI3K PTEN Autophagy
Oroxin B (Standard) is the analytical standard of Oroxin B. This product is intended for research and analytical applications. Oroxin B (OB) is a flavonoid isolated from traditional Chinese herbal medicine Oroxylum indicum (L.) Vent. Oroxin B (OB) possesses obvious inhibitory effect and induces early apoptosis rather than late apoptosis on liver cancer cells through upregulation of PTEN, down regulation of COX-2, VEGF, PI3K, and p-AKT . Oroxin B (OB) selectively induces tumor-suppressive ER stress in malignant lymphoma cells .

HY-P2813

Hirudin 1 Publications Verification	Cardiovascular Disease Structural Classification Natural Products Animals Classification of Application Fields Source classification Disease Research Fields Cancer	Thrombin Apoptosis
Hirudin is a thrombin inhibitor with blood anticoagulant property. Hirudin has potent anti-thrombotic, wound repair, anti-fibrosis, anti-tumor and anti-hyperuricemia effects. Hirudin also affects diabetic complications, cerebral hemorrhage, and others .

HY-16050R

Plitidepsin (Standard) Aplidine (Standard); PM90001 (Standard)	Structural Classification Microorganisms Marine natural products Source classification Other marine organisms	Reference Standards DNA/RNA Synthesis SARS-CoV
Plitidepsin (Standard) is the analytical standard of Plitidepsin. This product is intended for research and analytical applications. Plitidepsin (Aplidine) is a potent anti-cancer agent by targeting eEF1A2 ( K_D=80 nM) . Plitidepsin possesses antiviral activity and is against SARS-CoV-2 with an IC₉₀ of 0.88 nM. Plitidepsin is usually used for multiple myeloma and advanced cancer research, and has the potential for COVID-19 research .

HY-16050

Plitidepsin 3 Publications Verification Aplidine; PM90001	Structural Classification Microorganisms Marine natural products Source classification Other marine organisms	DNA/RNA Synthesis SARS-CoV
Plitidepsin (Aplidine) is a potent anti-cancer agent by targeting eEF1A2 ( K_D=80 nM) . Plitidepsin possesses antiviral activity and is against SARS-CoV-2 with an IC₉₀ of 0.88 nM. Plitidepsin is usually used for multiple myeloma and advanced cancer research, and has the potential for COVID-19 research .

HY-N0890

Tubeimoside I 4 Publications Verification Tubeimoside-1; Lobatoside-H	Triterpenes Structural Classification Classification of Application Fields Terpenoids Source classification Cucurbitaceae Plants Bolbostemma paniculaum (Maxim)Franguet Disease Research Fields Cancer	HSP NF-κB p38 MAPK Akt Autophagy Interleukin Related VEGFR
Tubeimoside I is an orally active HSPD1 inhibitor. Tubeimoside I inhibits NF-κB, MAPK, as well as regulates *eNOS-VEGF. Tubeimoside I induces cytoprotective Autophagy* via an Akt-mediated pathway. Tubeimoside I inhibits proinflammatory cytokine (IL-6 and IL-1β) production. Tubeimoside I exhibits anti-inflammatory activities. Tubeimoside I promotes angiogenesis and improves sepsis symptoms. Tubeimoside I is used in the research of inflammatory diseases, various cancers, sepsis and ischemic diseases .

HY-N0890R

Tubeimoside I (Standard) Tubeimoside-1 (Standard); Lobatoside-H (Standard)	Triterpenes Structural Classification Terpenoids Source classification Cucurbitaceae Plants Bolbostemma paniculaum (Maxim)Franguet	Reference Standards Apoptosis
Tubeimoside I (Standard) is the analytical standard of Tubeimoside I. This product is intended for research and analytical applications. Tubeimoside I is an orally active HSPD1 inhibitor. Tubeimoside I inhibits NF-κB, MAPK, as well as regulates *eNOS-VEGF. Tubeimoside I induces cytoprotective Autophagy* via an Akt-mediated pathway. Tubeimoside I inhibits proinflammatory cytokine (IL-6 and IL-1β) production. Tubeimoside I exhibits anti-inflammatory activities. Tubeimoside I promotes angiogenesis and improves sepsis symptoms. Tubeimoside I is used in the research of inflammatory diseases, various cancers, sepsis and ischemic diseases .

HY-N0103A

Sophocarpine monohydrate 5+ Cited Publications	Infection Alkaloids Piperidine Alkaloids Structural Classification Classification of Application Fields Leguminosae Source classification Sophora japonica L. Plants Inflammation/Immunology Disease Research Fields	Autophagy Apoptosis NF-κB PI3K Akt MEK ERK
Sophocarpine monohydrate is a PTEN activator and an inhibitor of PI3K/Akt, MEK/ERK, and NF-κB signaling pathways. Sophocarpine monohydrate upregulates PTEN expression and inhibits PI3K/Akt phosphorylation, arrests tumor cell cycle and induces apoptosis. Sophocarpine monohydrate inhibits MEK/ERK phosphorylation and VEGF secretion, reducing tumor cell migration. Sophocarpine monohydrate can also inhibit NF-κB activation and p38 and JNK phosphorylation, reduce the expression of inflammatory factors such as iNOS and COX-2, and activate the Nrf2/HO-1 pathway to reduce oxidative stress. Sophocarpine monohydrate has anti-tumor, anti-inflammatory, antioxidant and anti-apoptotic effects, and can be used in the research of cancers such as glioblastoma and colorectal cancer, inflammation-related diseases, and Doxorubicin (HY-15142A)-induced cardiac damage .

HY-N0103

Sophocarpine 5+ Cited Publications	Infection Alkaloids Piperidine Alkaloids Structural Classification Classification of Application Fields Leguminosae Source classification Sophora flavescens Aiton Plants Inflammation/Immunology Disease Research Fields	Autophagy Apoptosis NF-κB PI3K Akt MEK ERK PTEN
Sophocarpine is a PTEN activator and an inhibitor of PI3K/Akt, MEK/ERK, and NF-κB signaling pathways. Sophocarpine upregulates PTEN expression and inhibits PI3K/Akt phosphorylation, arrests tumor cell cycle and induces apoptosis. Sophocarpine inhibits MEK/ERK phosphorylation and VEGF secretion, reducing tumor cell migration. Sophocarpine can also inhibit NF-κB activation and p38 and JNK phosphorylation, reduce the expression of inflammatory factors such as iNOS and COX-2, and activate the Nrf2/HO-1 pathway to reduce oxidative stress. Sophocarpine has anti-tumor, anti-inflammatory, antioxidant and anti-apoptotic effects, and can be used in the research of cancers such as glioblastoma and colorectal cancer, inflammation-related diseases, and Doxorubicin (HY-15142A)-induced cardiac damage .

HY-N0103R

Sophocarpine (Standard)	Alkaloids Piperidine Alkaloids Structural Classification Leguminosae Source classification Sophora flavescens Aiton Plants	Reference Standards Autophagy Apoptosis NF-κB PI3K Akt MEK ERK
Sophocarpine (Standard) is the analytical standard of Sophocarpine (HY-N0103). This product is intended for research and analytical applications. Sophocarpine is a PTEN activator and an inhibitor of PI3K/Akt, MEK/ERK, and NF-κB signaling pathways. Sophocarpine upregulates PTEN expression and inhibits PI3K/Akt phosphorylation, arrests tumor cell cycle and induces apoptosis. Sophocarpine inhibits MEK/ERK phosphorylation and VEGF secretion, reducing tumor cell migration. Sophocarpine can also inhibit NF-κB activation and p38 and JNK phosphorylation, reduce the expression of inflammatory factors such as iNOS and COX-2, and activate the Nrf2/HO-1 pathway to reduce oxidative stress. Sophocarpine has anti-tumor, anti-inflammatory, antioxidant and anti-apoptotic effects, and can be used in the research of cancers such as glioblastoma and colorectal cancer, inflammation-related diseases, and Doxorubicin (HY-15142A)-induced cardiac damage .

Recombinant Proteins Recommended:

VEGF

Species:	Human (47) Rat (7) Mouse (18) Cynomolgus (4) Rabbit (2) Canine (1) Pig (2)
Tag:	His (43) SUMO (1) Tag Free (21) Strep (1) Avi (17) Fc (14)
Source:	HEK293 (57) CHO (2) P. pastoris (6) Sf9 insect cells (3) E. coli (11)

Cat. No.	Compare	Product Name	Species	Source

HY-P73556

	VEGF145 Protein, Human (HEK293, solution) VEGF-AA; MVCD1; VAS; Vascular endothelial growth factor A; VEGF; VPF	Human	HEK293
	VEGF145 Protein is a subtype of Vascular Endothelial Growth Factor A (VEGF-A). VEGF-A is a key member of the VEGF family of cytokines that can promote neovascularization and increase vascular permeability. VEGF145 Protein, Human (HEK293) is the recombinant human-derived VEGF145 protein, expressed by HEK293 , with tag free. The total length of VEGF145 Protein, Human (HEK293) is 145 a.a., with molecular weight of ~16.92 kDa.

HY-P70638

	VEGF164 Protein, Rat (P.pastoris) VEGF-AA; Vascular endothelial growth factor A; Vascular permeability factor; VEGF; VPF	Rat	P. pastoris
	The VEGF164 protein is a growth factor critical for vasculogenesis, vasculogenesis, and endothelial cell growth, inducing proliferation, promoting migration, inhibiting apoptosis, and enhancing vascular permeability. It binds to FLT1/VEGFR1, KDR/VEGFR2, heparan sulfate, heparin, NRP1 and DEAR/FBXW7-AS1 receptors. VEGF164 Protein, Rat (P.pastoris) is the recombinant rat-derived VEGF164 protein, expressed by P. pastoris , with tag free and A36T mutation.

HY-P70519

	VEGF121 Protein, Human (HEK293, His) VEGF-AA; Vascular endothelial growth factor A; Vascular permeability factor; VPF; VEGFA; VEGF	Human	HEK293
	VEGF121 Protein is a subtype of Vascular Endothelial Growth Factor A (VEGF-A). VEGF-A is a key member of the VEGF family of cytokines that can promote neovascularization and increase vascular permeability. VEGF121 Protein, Human (121a.a, HEK293, His) is the recombinant human-derived VEGF121 protein, expressed by HEK293 , with C-6*His labeled tag. The total length of VEGF121 Protein, Human (121a.a, HEK293, His) is 121 a.a., with molecular weight of 16-18 kDa.

HY-P7312

	VEGF164 Protein, Mouse 5+ Cited Publications VEGF-AA; rMuVEGF164; VPF	Mouse	E. coli
	VEGF164 Protein, Mouse is a potent mediator of angiogenesis and binds the semaphorin receptor, neuropilin1.

HY-P7311

	VEGF164 Protein, Rat (CHO) 3 Publications Verification rRtVEGF164; VEGF-AA; VPF	Rat	CHO
	VEGF164 Protein, Rat (CHO) is a potent mediator of angiogenesis and binds the semaphorin receptor, neuropilin1.

HY-P7110

	VEGF165 Protein, Human (P.pastoris) VEGF-AA; rHuVEGF165; VPF; Folliculostellate cell-derived growth factor; Glioma-derived endothelial cell mitogen	Human	P. pastoris
	VEGF165 Protein, Human (P.pastoris) is a Vascular Endothelial Growth Factor A (VEGF-A) isoform. VEGF is a heparin-binding growth factor specific for vascular endothelial cells that is able to induce angiogenesis.

HY-P7110A

	VEGF165 Protein, Human (HEK293) Maximum Cited Publications 9 Publications Verification VEGF-AA; rHuVEGF165; VPF; Folliculostellate cell-derived growth factor; Glioma-derived endothelial cell mitogen	Human	HEK293
	VEGF165 Protein, Human is a Vascular Endothelial Growth Factor A (VEGF-A) isoform. VEGF165 Protein is the growth factor that affects the angiogenesis, vasculogenesis and endothelial cell growth. VEGF165 Protein can binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin, and affects the motor neuron signaling pathway. VEGF165 Protein, Human (HEK293) is a human-derived VEGF165 Protein that can be expressed by HEK293.

HY-P73471

	VEGF121 Protein, Human (HEK293) VEGF-AA; MVCD1; VAS; Vascular endothelial growth factor A; VEGF; VPF	Human	HEK293
	VEGF121 Protein is a subtype of Vascular Endothelial Growth Factor A (VEGF-A). VEGF-A is a key member of the VEGF family of cytokines that can promote neovascularization and increase vascular permeability. VEGF121 Protein, Human (HEK293) is the recombinant human-derived VEGF121 protein, expressed by HEK293 , with tag free. The total length of VEGF121 Protein, Human (HEK293) is 147 a.a., with molecular weight of ~19.9 & 17.0 kDa, respectively.

HY-P72775

	VEGF120 Protein, Mouse 1 Publications Verification VEGF-AA; Vascular endothelial growth factor A; VPF; VEGFA	Mouse	E. coli
	VEGF-A Protein is a key member of the VEGF family of cytokines.VEGF-A participates in angiogenesis, vasculogenesis, and endothelial cell growth, inducing endothelial cell proliferation, promoting cell migration, inhibiting cell apoptosis, and inducing vascular permeability.VEGF-A stimulates endothelial cell mitogenesis and cell migration.VEGF120 Protein, Mouse is the recombinant mouse-derived VEGF120 protein, expressed by E.coli , with tag free.

HY-P77279

	VEGF183 Protein, Human (sf9) VEGF-AA; Vascular endothelial growth factor A; Vascular permeability factor; VPF; VEGF	Human	Sf9 insect cells
	VEGF183 Protein is a subtype of Vascular Endothelial Growth Factor A (VEGF-A). VEGF-A is a key member of the VEGF family of cytokines that can promote neovascularization and increase vascular permeability. VEGF183 Protein, Human (sf9) is the recombinant human-derived VEGF183 protein, expressed by Sf9 insect cells , with tag free. The total length of VEGF183 Protein, Human (sf9) is 183 a.a., with molecular weight of ~21 KDa.

HY-P703971

	VEGF110 Protein, Human (HEK293) VEGF; VEGFA; L-VEGF; N-VEGF; VPF; MVCD1	Human	HEK293

HY-P703478

	VEGF165 Protein, Human (HEK293, StrepⅡ, His) VEGF	Human	HEK293
	VEGF165 Protein is a subtype of Vascular Endothelial Growth Factor A (VEGF-A). VEGF-A is a key member of the VEGF family of cytokines that can promote neovascularization and increase vascular permeability. VEGF165 Protein, Human (HEK293, Strep, His) is the recombinant human-derived VEGF165, expressed by HEK293, with Strep, His labeled tag.

HY-P7421

	VEGF164 Protein, Mouse (P.pastoris) 1 Publications Verification VEGF-AA; rMuVEGF164; VPF	Mouse	P. pastoris
	VEGF164 Protein, Mouse (P.pastoris), a VEGF isoform splice variant, is more potent at inducing endothelial ICAM-1 expression by VEGFR-2, leukocyte migration by VEGFR-1, and inflammation and angiogenesis in the adult cornea.

HY-P78377

	VEGF121 Protein, Human (HEK293, His-Avi) VEGF-AA; MVCD1; VAS; Vascular endothelial growth factor A; VEGF; VPF	Human	HEK293
	VEGF121 Protein is a subtype of Vascular Endothelial Growth Factor A (VEGF-A). VEGF-A is a key member of the VEGF family of cytokines that can promote neovascularization and increase vascular permeability. VEGF121 Protein, Human (HEK293, His-Avi) is the recombinant human-derived VEGF121 protein, expressed by HEK293 , with C-Avi, C-His labeled tag. The total length of VEGF121 Protein, Human (HEK293, His-Avi) is 121 a.a., with molecular weight of ~18 kDa & 22-25 kDa, respectively.

HY-P704409

	VEGF121 Protein, Human (HEK293, N-His) VEGF-AA; MVCD1; VAS; Vascular endothelial growth factor A; VEGF; VPF	Human	HEK293
	Vascular Endothelial Growth Factor A (VEGF-A) is a key member of the VEGF family of cytokines that can promote neovascularization and increase vascular permeability. VEGF121 Protein, Human (HEK293, N-His) is the recombinant human-derived VEGF121 protein, expressed by HEK293, with N-His labeled tag.

HY-P7420

	VEGF121 Protein, Human (120 a.a) 2 Publications Verification VEGF-AA; rHuVEGF-121; VPF	Human	E. coli
	VEGF121 Protein, Human (120 a.a), a VEGF isoform splice variant, cannot bind to heparin. VEGF121 Protein is predictor for survival in activated B-cell-like diffuse large B-cell lymphoma and is related to an immune response gene signature conserved in cancers.

HY-P76122

	VEGF164 Protein, Rat (sf9) VEGF-AA; Vascular endothelial growth factor A; Vascular permeability factor; VPF; VEGFA; VEGFA164; VEGF164	Rat	Sf9 insect cells
	The VEGF164 protein is a growth factor critical for vasculogenesis, vasculogenesis, and endothelial cell growth, inducing proliferation, promoting migration, inhibiting apoptosis, and enhancing vascular permeability. It binds to FLT1/VEGFR1, KDR/VEGFR2, heparan sulfate, heparin, NRP1 and DEAR/FBXW7-AS1 receptors. VEGF164 Protein, Rat (sf9) is the recombinant rat-derived VEGF164 protein, expressed by Sf9 insect cells , with tag free.

HY-P73473

	VEGF-A Protein, Canine (HEK293) VEGFA; Vascular endothelial growth factor A; VPF; VEGF	Canine	HEK293
	VEGFA Protein is a vascular endothelial growth factor that is active in angiogenesis and endothelial cell growth. VEGFA Protein induces endothelial cell proliferation, promotes cell migration, inhibits cell apoptosis, and induces vascular permeability. VEGFA Protein consists of 214 amino acids (M1-R214). VEGF-A Protein, Canine (HEK293) is the recombinant canine-derived VEGF-A protein, expressed by HEK293 , with tag free.

HY-P72430

	VEGF-D Protein, Mouse (HEK293, His) Vascular endothelial growth factor D; VEGF-D; FIGF	Mouse	HEK293
	VEGF-D Protein, a versatile growth factor, orchestrates angiogenesis, lymphangiogenesis, and endothelial cell growth. It stimulates proliferation, migration, and influences vessel permeability. VEGF-D binds VEGFR-3, triggering crucial signaling for vascular development. Structurally, VEGF-D is a non-covalent homodimer, emphasizing its intricate role in vascular processes. VEGF-D Protein, Mouse (HEK293, His) is the recombinant mouse-derived VEGF-D protein, expressed by HEK293 , with C-6*His labeled tag.

HY-P72431

	VEGF-B Protein, Human (HEK293, Fc) 2 Publications Verification Vascular endothelial growth factor B; VEGF-B; VRF	Human	HEK293
	VEGF-B protein is an endothelial cell-specific growth factor with VEGF-B167 and VEGF-B186 isoforms and has a unique binding ability to heparin and Neuropilin-1. VEGF-B Protein, Human (HEK293, Fc) is the recombinant human-derived VEGF-B protein, expressed by HEK293 , with N-hFc labeled tag.

HY-P73474

	VEGF-D Protein, Mouse (HEK293, Fc) Vascular endothelial growth factor D; VEGF-D; FIGF	Mouse	HEK293
	VEGF-D Protein, a versatile growth factor, orchestrates angiogenesis, lymphangiogenesis, and endothelial cell growth. It stimulates proliferation, migration, and influences vessel permeability. VEGF-D binds VEGFR-3, triggering crucial signaling for vascular development. Structurally, VEGF-D is a non-covalent homodimer, emphasizing its intricate role in vascular processes. VEGF-D Protein, Mouse (HEK293, Fc) is the recombinant mouse-derived VEGF-D protein, expressed by HEK293 , with N-hFc labeled tag.

HY-P73475

	VEGF-D Protein, Rat (HEK293, Fc) Vascular endothelial growth factor D; VEGF-D; FIGF	Rat	HEK293
	VEGF-D, a growth factor, stimulates proliferation, migration, and vessel permeability. It is crucial for vascular development and maintenance of lymphatic endothelium. VEGF-D binds and activates VEGFR-3, initiating essential signaling pathways. Structurally, it forms a non-covalent homodimer, playing an intricate role in vascular processes. VEGF-D Protein, Rat (HEK293, Fc) is the recombinant rat-derived VEGF-D protein, expressed by HEK293 , with N-hFc labeled tag.

HY-P704256

	VEGF-B Protein, Human (HEK293,His) Vascular endothelial growth factor B; VEGF-B; VRF	Human	HEK293
	VEGF-BB protein is an endothelial cell-specific growth factor with VEGF-B167 and VEGF-B186 isoforms and has a unique binding ability to heparin and Neuropilin-1. VEGF-B Protein, Human (HEK293,His) is the recombinant human-derived VEGF-B protein, expressed by HEK293, with C-His labeled tag.

HY-P70761

	VEGF164 Protein, Mouse (164a.a, P.pastoris) VEGF-AA; Vascular endothelial growth factor A; Vascular permeability factor; VPF; VEGFA; VEGFA164; VEGF164	Mouse	P. pastoris
	VEGF-A Protein is a key member of the VEGF family of cytokines.VEGF-A participates in angiogenesis, vasculogenesis, and endothelial cell growth, inducing endothelial cell proliferation, promoting cell migration, inhibiting cell apoptosis, and inducing vascular permeability.VEGF-A stimulates endothelial cell mitogenesis and cell migration.VEGF164 Protein, Mouse (P.pastoris) is the recombinant mouse-derived VEGF164 protein, expressed by P.pastoris , with tag free.

HY-P78378

	VEGF165 Protein, Human (HEK293, His-Avi) VEGF-AA; VEGF; MVCD1; VAS; VEGFMGC70609; VPF; RP1-261G23.1; MGC70609	Human	HEK293
	VEGF165 Protein is a subtype of Vascular Endothelial Growth Factor A (VEGF-A). VEGF-A is a key member of the VEGF family of cytokines that can promote neovascularization and increase vascular permeability. VEGF165 Protein, Human (HEK293, His-Avi) is the recombinant human-derived VEGF165 protein, expressed by HEK293 , with C-Avi, C-His labeled tag. The total length of VEGF165 Protein, Human (HEK293, His-Avi) is 165 a.a., with molecular weight of 28-32 kDa.

HY-P78228

	VEGF121 Protein, Human (Biotinylated, HEK293, His-Avi) VEGF-AA; VEGF; MVCD1; VAS; VEGFMGC70609; VPF; RP1-261G23.1; MGC70609	Human	HEK293
	VEGF121 Protein is a subtype of Vascular Endothelial Growth Factor A (VEGF-A). VEGF-A is a key member of the VEGF family of cytokines that can promote neovascularization and increase vascular permeability. VEGF121 Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived VEGF121 protein, expressed by HEK293 , with C-Avi, C-His labeled tag. The total length of VEGF121 Protein, Human (Biotinylated, HEK293, His-Avi) is 121 a.a., with molecular weight of ~18 kDa & 22-25 kDa, respectively.

HY-P78229

	VEGF165 Protein, Human (Biotinylated, HEK293, His-Avi) VEGF-AA; VEGF; MVCD1; VAS; VEGFMGC70609; VPF; RP1-261G23.1; MGC70609	Human	HEK293
	VEGF165 Protein is a subtype of Vascular Endothelial Growth Factor A (VEGF-A). VEGF-A is a key member of the VEGF family of cytokines that can promote neovascularization and increase vascular permeability. VEGF165 Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived VEGF165 protein, expressed by HEK293 , with C-Avi, C-His labeled tag. The total length of VEGF165 Protein, Human (Biotinylated, HEK293, His-Avi) is 165 a.a., with molecular weight of 28-32 kDa.

HY-P77864

	VEGF-C Protein, Human (HEK293, His-Avi) VEGFC; VEGF-CC; VEGFc; Flt4-L; VRP;	Human	HEK293
	VEGF-C protein is an important member of the PDGF/VEGF growth factor family and plays a role in important cell signaling pathways. As part of this family, VEGF-C may share features with related proteins that promote cell growth, angiogenesis, and lymphangiogenesis. VEGF-C Protein, Human (HEK293, His-Avi) is the recombinant human-derived VEGF-C protein, expressed by HEK293 , with C-Avi, C-His labeled tag.

HY-P72280

	VEGF-A Protein, Pig (His) VEGFA; VEGFVascular endothelial growth factor A; VEGF-A; Vascular permeability factor; VPF	Pig	E. coli
	The VEGF-A protein is a multifunctional growth factor that is essential for promoting angiogenesis, vasculogenesis, and endothelial cell growth. Its multiple effects include inducing endothelial cell proliferation, promoting migration, inhibiting apoptosis, and increasing vascular permeability. VEGF-A Protein, Pig (His) is the recombinant pig-derived VEGF-A protein, expressed by E. coli , with N-6*His labeled tag.

HY-P77865

	VEGF-C Protein, Human (Biotinylated, HEK293, His-Avi) VEGFC; VEGF-CC; VEGFc; Flt4-L; VRP;	Human	HEK293
	VEGF-C protein is an important member of the PDGF/VEGF growth factor family and plays a role in important cell signaling pathways. As part of this family, VEGF-C may share features with related proteins that promote cell growth, angiogenesis, and lymphangiogenesis. VEGF-C Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived VEGF-C protein, expressed by HEK293 , with C-Avi, C-His labeled tag.

HY-P704092

	VEGF206 Protein, Human (His) VEGFA; VEGFVascular endothelial growth factor A; VEGF-A; Vascular permeability factor; VPF	Human	E. coli
	Vascular Endothelial Growth Factor A (VEGF-A) is a key member of the VEGF family of cytokines that can promote neovascularization and increase vascular permeability. VEGF206 Protein, Human (His) is the recombinant human-derived VEGF206 protein, expressed by E. coli, with N-6*His labeled tag.

HY-P705280

	VEGF-D Protein, Mouse (Biotinylated, HEK293, His-Avi) Vascular endothelial growth factor D; VEGF-D; FIGF	Mouse	HEK293

HY-P70458A

	VEGF165 Protein, Human (HEK293, C-His) 1 Publications Verification Vascular Endothelial Growth Factor Isoform 165; VEGF165	Human	HEK293
	VEGF165 Protein is a subtype of Vascular Endothelial Growth Factor A (VEGF-A). VEGF-A is a key member of the VEGF family of cytokines that can promote neovascularization and increase vascular permeability. VEGF165 Protein, Human (HEK293, C-His) is the recombinant human-derived VEGF165 protein, expressed by HEK293 , with C-10*His labeled tag. The total length of VEGF165 Protein, Human (HEK293, C-His) is 165 a.a., with molecular weight of 20-23 kDa.

HY-P700496

	VEGF-A Protein, Rabbit (His-SUMO) VEGFA; VPF; VEGF; MVCD1; vascular endothelial growth factor A; vascular permeability factor	Rabbit	E. coli
	The VEGF-A protein is a multifunctional growth factor that is essential for promoting angiogenesis, vasculogenesis, and endothelial cell growth. Its multiple effects include inducing endothelial cell proliferation, promoting migration, inhibiting apoptosis, and increasing vascular permeability. VEGF-A Protein, Rabbit (His-SUMO) is the recombinant Rabbit-derived VEGF-A protein, expressed by E. coli , with N-SUMO, N-6*His labeled tag.

HY-P700497

	VEGF-A Protein, Rabbit (P. pastoris, His) VEGFA; VPF; VEGF; MVCD1; vascular endothelial growth factor A; vascular permeability factor	Rabbit	P. pastoris
	The VEGF-A protein is a multifunctional growth factor that is essential for promoting angiogenesis, vasculogenesis, and endothelial cell growth. Its multiple effects include inducing endothelial cell proliferation, promoting migration, inhibiting apoptosis, and increasing vascular permeability. VEGF-A Protein, Rabbit (P. pastoris, His) is the recombinant Rabbit-derived VEGF-A protein, expressed by P. pastoris , with N-6*His labeled tag.

HY-P70495

	VEGF-D Protein, Human (HEK293, His) Vascular Endothelial Growth Factor D; VEGF-D; c-Fos-Induced Growth Factor; FIGF; VEGFD	Human	HEK293
	VEGF-D protein is a potent growth factor in angiogenesis, lymphangiogenesis, and endothelial cell growth, playing a key role in stimulating cell proliferation, migration, and affecting vascular permeability. It may be involved in the formation of veins and lymphatic vasculature during embryogenesis, suggesting that it plays a key role in vascular development. VEGF-D Protein, Human (HEK293, His) is the recombinant human-derived VEGF-D protein, expressed by HEK293 , with C-6*His labeled tag.

HY-P703960

	VEGF-D Protein, Human (117a.a, HEK293, His) FIGF; VEGFD	Human	HEK293
	VEGF-DD protein is a potent growth factor in angiogenesis, lymphangiogenesis, and endothelial cell growth, playing a key role in stimulating cell proliferation, migration, and affecting vascular permeability. It may be involved in the formation of veins and lymphatic vasculature during embryogenesis, suggesting that it plays a key role in vascular development. VEGF-D Protein, Human (117a.a, HEK293, His) is the recombinant human-derived VEGF-D protein, expressed by HEK293, with C-His labeled tag.

HY-P7314

	VEGF-D Protein, Human (CHO) rHuVEGF-D; Vascular endothelial growth factor D; FIGF	Human	CHO
	VEGF-D Protein, Human (CHO) is a regulator of both angiogenesis and lymphangiogenesis.

HY-P70501

	VEGF-C Protein, Human (196a.a, HEK293, His) Vascular Endothelial Growth Factor C; VEGF-C; Flt4 Ligand; Flt4-L; Vascular Endothelial Growth Factor-Related Protein; VRP; VEGFC	Human	HEK293
	The VEGF-C protein is a potent growth factor in angiogenesis and endothelial cell growth, stimulating cell proliferation and migration while affecting vascular permeability. It plays a critical role in embryonic vein and lymphangiogenesis and maintains adult differentiated lymphatic endothelium. VEGF-C Protein, Human (196a.a, HEK293, His) is the recombinant human-derived VEGF-C protein, expressed by HEK293 , with C-6*His labeled tag.

HY-P74474

	VEGF-C Protein, Mouse/Rat (HEK293, His) 3 Publications Verification Flt4-L; vascular endothelial growth factor C; VEGFC; VRP	Mouse;Rat	HEK293
	VEGF-C protein stimulates cell proliferation, migration, and vascular permeability, which are critical for angiogenesis and endothelial cell dynamics. It plays a crucial role in the development of the venous and lymphatic vasculature during embryogenesis and in the maintenance of adult lymphatic endothelium. VEGF-C Protein, Mouse/Rat (HEK293, His) is the recombinant mouse, rat-derived VEGF-C protein, expressed by HEK293 , with C-6*His labeled tag.

HY-P74475

	VEGF-C Protein, Mouse/Rat (HEK293, Fc) Flt4-L; vascular endothelial growth factor C; VEGFC; VRP	Rat;Mouse	HEK293
	VEGF-C protein stimulates cell proliferation, migration, and vascular permeability, which are critical for angiogenesis and endothelial cell dynamics. It plays a crucial role in the development of the venous and lymphatic vasculature during embryogenesis and in the maintenance of adult lymphatic endothelium. VEGF-C Protein, Mouse/Rat (HEK293, Fc) is the recombinant rat, mouse-derived VEGF-C protein, expressed by HEK293 , with N-hFc labeled tag.

HY-P78686

	VEGF120 Protein, Mouse (HEK293) RP1-261G23.1; MGC70609; MVCD1; VEGFA; VPF	Mouse	HEK293
	VEGF120 Protein, Mouse (HEK293) is the recombinant mouse-derived VEGF120 protein, expressed by HEK293, with tag free. The total length of VEGF120 Protein, Mouse (HEK293) is 120 a.a., with molecular weight of 18-22 kDa.

HY-P78537

	VEGFR-1 Protein, Human (HEK293, His-Avi) FLT; FLT1; Flt-1; FRT; VEGF R1; VEGFR1	Human	HEK293
	The VEGFR-1 protein is a tyrosine protein kinase that acts as a cell surface receptor for VEGFA, VEGFB, and PGF. It plays a crucial role in embryonic vasculature development, regulation of angiogenesis, cell survival, migration, macrophage function, chemotaxis, and cancer cell invasion. VEGFR-1 Protein, Human (HEK293, His-Avi) is the recombinant human-derived VEGFR-1 protein, expressed by HEK293 , with C-His, C-Avi labeled tag.

HY-P78812

	VEGF120 Protein, Mouse (Biotinylated, His-Avi) RP1-261G23.1; MGC70609; MVCD1; VEGFA; VPF	Mouse	E. coli
	VEGF-A Protein is a key member of the VEGF family of cytokines. VEGF-A participates in angiogenesis, vasculogenesis, and endothelial cell growth, inducing endothelial cell proliferation, promoting cell migration, inhibiting cell apoptosis, and inducing vascular permeability. VEGF-A stimulates endothelial cell mitogenesis and cell migration. VEGF120 Protein, Mouse (Biotinylated, His-Avi) is the recombinant mouse-derived VEGF120 protein, expressed by E. coli , with N-His, N-Avi labeled tag. The total length of VEGF120 Protein, Mouse (Biotinylated, His-Avi) is 120 a.a., with molecular weight of 22-24 kDa.

HY-P7313

	VEGF-C Protein, Human (116a.a, HEK293) rHuVEGF-C; Vascular endothelial growth factor C; Flt4-L; VRP	Human	HEK293
	VEGF-C Protein, Human (116a.a, HEK293) functions in lymphangiogenesis, where it acts on lymphatic endothelial cells (LECs) primarily via its receptor VEGFR-3 promoting survival, growth and migration.

HY-P73529

	VEGF-C Protein, Human (125a.a, HEK293, His) Flt4-L; vascular endothelial growth factor C; VEGFC; VRP	Human	HEK293
	The VEGF-C protein is a potent growth factor in angiogenesis and endothelial cell growth, stimulating cell proliferation and migration while affecting vascular permeability. It plays a critical role in embryonic vein and lymphangiogenesis and maintains adult differentiated lymphatic endothelium. VEGF-C Protein, Human (125a.a, HEK293, His) is the recombinant human-derived VEGF-C protein, expressed by HEK293 , with C-His labeled tag.

HY-P78230

	VEGFR-1 Protein, Human (Biotinylated, HEK293, His-Avi) FLT; FLT1; Flt-1; FRT; VEGF R1; VEGFR1	Human	HEK293
	The VEGFR-1 protein is a tyrosine protein kinase that acts as a cell surface receptor for VEGFA, VEGFB, and PGF. It plays a crucial role in embryonic vasculature development, regulation of angiogenesis, cell survival, migration, macrophage function, chemotaxis, and cancer cell invasion. VEGFR-1 Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived VEGFR-1 protein, expressed by HEK293 , with C-Avi, C-His labeled tag.

HY-P78813

	VEGF165 Protein, Human (Biotinylated, HEK293, Avi) 1 Publications Verification RP1-261G23.1; MGC70609; MVCD1; VEGFA; VPF	Human	HEK293
	VEGF165 is a member of the PDGF/VEGF family encoding a heparin-binding homodimer that is crucial in inducing vascular endothelial cell proliferation and migration during angiogenesis. The VEGF gene is critical for blood vessel development, and its disruption leads to abnormal blood vessel formation in mouse embryos. VEGF165 Protein, Human (Biotinylated, HEK293, Avi) is the recombinant human-derived VEGF165 protein, expressed by HEK293 , with N-Avi labeled tag.

HY-P705206

	VEGF-D Protein, Cynomolgus (Biotinylated, HEK293, His-Avi) Vascular endothelial growth factor D; VEGFD; c-Fos-induced growth factor	Cynomolgus	HEK293

HY-P78814

	VEGF164 Protein, Mouse (Biotinylated, HEK293, His-Avi) RP1-261G23.1; MGC70609; MVCD1; VEGFA; VPF	Mouse	HEK293
	VEGF-A Protein is a key member of the VEGF family of cytokines. VEGF-A participates in angiogenesis, vasculogenesis, and endothelial cell growth, inducing endothelial cell proliferation, promoting cell migration, inhibiting cell apoptosis, and inducing vascular permeability. VEGF-A stimulates endothelial cell mitogenesis and cell migration. VEGF164 Protein, Mouse (Biotinylated, HEK293, His-Avi) is the recombinant mouse-derived VEGF164 protein, expressed by HEK293 , with N-His, N-Avi labeled tag. The total length of VEGF164 Protein, Mouse (Biotinylated, HEK293, His-Avi) is 164 a.a., with molecular weight of 28-33 kDa.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-W653893

Taurocholic acid-d5 sodium
Taurocholic acid-d₅ (sodium) is deuterium labeled Taurocholic acid (sodium). Taurocholic acid sodium (Sodium taurocholate) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid sodium has immunoregulation effect .

HY-128922S

Dexamethasone palmitate-d31
Dexamethasone palmitate-d31 is the deuterium labeled Dexamethasone palmitate(HY-128922).Dexamethasone palmitate (DXP) is a proagent of Dexamethasone (HY-14648). Dexamethasone palmitate can be used for the research of inflammation .

HY-B0239S2

Threo-Chloramphenicol-d6

Threo-Chloramphenicol-d₆ is the deuterium labeled Chloramphenicol . Chloramphenicol is an orally active, potent and broad-spectrum antibiotic. Chloramphenicol shows antibacterial activity. Chloramphenicol represses the oxygen-labile transcription factor and hypoxia inducible factor-1 alpha (HIF-1α) in hypoxic A549 and H1299 cells. Chloramphenicol suppresses the mRNA levels of vascular endothelial growth factor (VEGF) and glucose transporter 1, eventually decreasing VEGF release. Chloramphenicol can be used for anaerobic infections and lung cancer research .

HY-W653842

Taurocholic acid-d8 sodium
Taurocholic acid-d₈ (sodium) is deuterium labeled Taurocholic acid (sodium). Taurocholic acid sodium (Sodium taurocholate) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid sodium has immunoregulation effect .

HY-B1788S2

Taurocholic acid-d5
Taurocholic acid-d₅ (Taurocholic Acid-d₅) is deuterium labeled Taurocholic acid. Taurocholic acid (N-Choloyltaurine) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid has immunoregulation effect .

HY-121356S

Carebastine-d5
Carebastine-d₅ is the deuterium labeled Carebastine. Carebastine is the active metabolite of Ebastine. Carebastine is a histamine H1 receptor antagonist. Carebastine inhibits VEGF-induced HUVEC and HPAEC proliferation, migration and angiogenesis in a dose-dependent manner . Carebastine suppresses the expression of macrophage migration inhibitory factor .

HY-121356S1

Carebastine-d5 Methyl Ester
Carebastine-d₅ Methyl Ester is the deuterium labeled Carebastine. Carebastine is the active metabolite of Ebastine. Carebastine is a histamine H1 receptor antagonist. Carebastine inhibits VEGF-induced HUVEC and HPAEC proliferation, migration and angiogenesis in a dose-dependent manner . Carebastine suppresses the expression of macrophage migration inhibitory factor .

HY-B0223S4

Albendazole-d3-1

Albendazole-d₃-1 (SKF-62979-d₃-1) is the deuterium labeled Albendazole (HY-B0223). Albendazole (SKF-62979) is an orally active and broad-spectrum parasiticide with high effectiveness and low host toxicity, is used for the research of gastrointestinal parasites in humans and animals. Albendazole induces apoptosis and autophagy in cancer cells. Albendazole also inhibits tubulin polymerization and HIF-1α, VEGF expression, has antioxidant activity, and inhibits the glycolytic process in cancer cells .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P80929

	VEGFA Antibody (YA013) VEGFA; VEGF; Vascular endothelial growth factor A; VEGF-A; Vascular permeability factor; VPF	WB	Human, Mouse, Rat
	VEGFA Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 27 kDa, targeting to VEGFA. It can be used for WB assays with tag free, in the background of Human, Mouse, Rat.

HY-P84117

	VEGFA Antibody (YA3814) VPF; VEGF; MVCD1	WB, ICC/IF, ELISA	Human
	VEGFA Antibody (YA3814) is a mouse-derived and non-conjugated IgG1 antibody, targeting to VEGFA. It can be applicated for WB, ICC/IF, ELISA assays, in the background of human.

HY-P80370

	VEGF Receptor 2 Antibody (YA014) VEGFR-2; FLK-1; KDR	WB, ICC/IF, IHC-P, IP	Human, Rat
	VEGF Receptor 2 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 152 kDa, targeting to VEGF Receptor 2. It can be used for WB,ICC,IHC-P,IP assays with tag free, in the background of Human, Rat.

HY-P80928

	VEGF Receptor 1 Antibody (YA015) VEGFR-1; VEGF Receptor 1; FLT-1; FLT; FRT; VEGFR1; Fms-like tyrosine kinase 1; Tyrosine-protein kinase FRT	WB, IHC-P, IP	Human, Mouse, Rat
	VEGF Receptor 1 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 151 kDa, targeting to VEGF Receptor 1. It can be used for WB,IHC-P,IP assays with tag free, in the background of Human, Mouse, Rat.

HY-P81643

	VEGF Receptor2 Antibody KDR; FLK1; VEGFR2; Vascular endothelial growth factor receptor 2; VEGFR-2; Fetal liver kinase 1; FLK-1; Kinase insert domain receptor; KDR; Protein-tyrosine kinase receptor flk-1; CD antigen CD309	WB, IHC-P, IHC-F, ICC/IF, ELISA	Human, Mouse
	VEGFR2 Antibody is a non-conjugated IgG antibody, targeting VEGFR2, with a predicted molecular weight of 152 kDa. VEGFR2 Antibody (YA1388) can be used for WB,IHC-F,IHC-P,ICC/IF,ELISA experiment in human, mouse background.

HY-P85795

	VEGF-A Antibody (YA5487) VEGFA; VEGF; Vascular endothelial growth factor A; VEGF-A; Vascular permeability factor; VPF	WB, ICC/IF, ELISA	Human, Mouse, Rat
	VEGF-A Antibody (YA5487) is a mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to VEGF-A. It can be applicated for WB, ICC/IF, ELISA assays, in the background of human, mouse, rat.

HY-P86376

	VEGF-A Antibody (YA6068) VEGFA; VEGF; Vascular endothelial growth factor A; VEGF-A; Vascular permeability factor; VPF	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	VEGF-A Antibody (YA6068) is a rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to VEGF-A. It can be applicated for WB, IHC-P, ICC/IF, IP, ELISA assays, in the background of human, mouse, rat.

HY-P82882

	VEGFB Antibody (YA2627) VEGFB; VRF; Vascular endothelial growth factor B; VEGF-B; VEGF-related factor; VRF	WB	Human, Mouse
	VEGFB Antibody (YA2627) is a non-conjugated IgG antibody, targeting VEGFB, with a predicted molecular weight of 22 kDa (observed band size: 16-62 kDa). VEGFB Antibody (YA2627) can be used for WB experiment in human, mouse background.

HY-P86118

	VEGF Receptor 2 Antibody (YA5810) Vascular endothelial growth factor receptor 2; VEGFR-2; Fetal liver kinase 1; FLK-1; Kinase insert domain receptor; KDR; Protein-tyrosine kinase receptor flk-1; CD antigen CD309;	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	VEGF Receptor 2 Antibody (YA5810) is a rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to VEGF Receptor 2. It can be applicated for WB, IHC-P, ICC/IF, IP, ELISA assays, in the background of human, mouse, rat.

HY-P83246

	*EG VEGF* Antibody (YA2991)** EGVEGF; Mambakine; PK1; PRK1; PROK1; Prokineticin-1	WB, FC	Human, Mouse
	EG VEGF Antibody (YA2991) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2991), targeting EG VEGF, with a predicted molecular weight of 12 kDa (observed band size: 12 kDa). EG VEGF Antibody (YA2991) can be used for WB, FC experiment in human, mouse background.

HY-P83810

	Neuropilin-1 Antibody (YA3507) NRP1; NP1; NRP; BDCA4; CD304; VEGF165R	WB, FC, ELISA	Human
	Neuropilin-1 Antibody (YA3507) is a mouse-derived and non-conjugated IgG1 antibody, targeting to Neuropilin-1. It can be applicated for WB, FC, ELISA assays, in the background of human.

HY-P82086

	Neuropilin 1 Antibody (YA1831) NRP1; NRP; VEGF165R; Neuropilin-1; Vascular endothelial cell growth factor 165 receptor; CD antigen CD304	WB, IHC-P, ICC/IF, IP, FC	Human, Mouse, Rat
	Neuropilin 1 Antibody (YA1831) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1831), targeting Neuropilin 1, with a predicted molecular weight of 103 kDa (observed band size: 125-135 kDa). Neuropilin 1 Antibody (YA1831) can be used for WB, IHC-P, ICC/IF, IP, FC experiment in human, mouse, rat background.

HY-P86601

	Neuropilin 1 Antibody (YA6293) NRP1; NRP; VEGF165R; Neuropilin-1; Vascular endothelial cell growth factor 165 receptor; CD antigen CD304	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	Neuropilin 1 Antibody (YA6293) is a rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Neuropilin 1. It can be applicated for WB, IHC-P, ICC/IF, IP, ELISA assays, in the background of human, mouse, rat.